[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 31 of about 31
1. Mansouri M, Rose PP, Moses AV, Früh K: Remodeling of endothelial adherens junctions by Kaposi's sarcoma-associated herpesvirus. J Virol; 2008 Oct;82(19):9615-28
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Remodeling of endothelial adherens junctions by Kaposi's sarcoma-associated herpesvirus.
  • We now demonstrate that the transmembrane ubiquitin ligase K5/MIR-2 of Kaposi's sarcoma-associated herpesvirus targets VE-cadherin for ubiquitin-mediated destruction, thus disturbing EC adhesion.
  • Our data represent the first example of a viral protein targeting adherens junction proteins and suggest that K5 contributes to EC proliferation, vascular leakage, and the reprogramming of the EC proteome during Kaposi's sarcoma tumorigenesis.

  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Med. 2003 Mar;9(3):300-6 [12592400.001]
  • [Cites] J Biol Chem. 2003 May 23;278(21):19199-208 [12626512.001]
  • [Cites] J Cell Biol. 2003 May 26;161(4):793-804 [12771128.001]
  • [Cites] Cell Biochem Biophys. 2003;38(3):305-22 [12794270.001]
  • [Cites] Microbiol Mol Biol Rev. 2003 Jun;67(2):175-212, table of contents [12794189.001]
  • [Cites] J Virol. 2003 Jul;77(14):8019-30 [12829841.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8490-5 [12832621.001]
  • [Cites] J Virol. 2003 Sep;77(17):9669-84 [12915579.001]
  • [Cites] Annu Rev Microbiol. 2003;57:609-39 [14527293.001]
  • [Cites] Nat Rev Cancer. 2003 Oct;3(10):756-67 [14570040.001]
  • [Cites] J Virol. 2003 Nov;77(22):12276-84 [14581564.001]
  • [Cites] J Virol. 2004 Feb;78(3):1109-20 [14722266.001]
  • [Cites] J Biol Chem. 2004 Feb 20;279(8):6526-33 [14660654.001]
  • [Cites] J Virol. 2004 Apr;78(7):3601-20 [15016882.001]
  • [Cites] BMC Cancer. 2003 Mar 18;3:7 [12697073.001]
  • [Cites] Thromb Haemost. 2005 Jun;93(6):1041-6 [15968386.001]
  • [Cites] Science. 2005 Jul 1;309(5731):127-30 [15994556.001]
  • [Cites] Oncogene. 2005 Oct 6;24(44):6617-25 [16007161.001]
  • [Cites] Eur J Histochem. 2005 Jul-Sep;49(3):273-84 [16216813.001]
  • [Cites] J Virol. 2005 Nov;79(22):14371-82 [16254371.001]
  • [Cites] J Virol. 2005 Dec;79(24):15099-106 [16306581.001]
  • [Cites] Blood. 2006 Sep 15;108(6):1932-40 [16601245.001]
  • [Cites] J Virol. 2006 Nov;80(21):10497-505 [16920823.001]
  • [Cites] Curr Top Microbiol Immunol. 2007;312:211-44 [17089799.001]
  • [Cites] PLoS Pathog. 2006 Oct;2(10):e107 [17238276.001]
  • [Cites] Cell Cycle. 2004 May;3(5):571-3 [15107603.001]
  • [Cites] Hepatology. 2004 Jun;39(6):1683-93 [15185310.001]
  • [Cites] Nat Genet. 2004 Jul;36(7):683-5 [15220917.001]
  • [Cites] Nat Genet. 2004 Jul;36(7):687-93 [15220918.001]
  • [Cites] Cell. 2005 Dec 2;123(5):889-901 [16325582.001]
  • [Cites] Exp Cell Res. 2006 Feb 15;312(4):457-67 [16368435.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18431-6 [16344472.001]
  • [Cites] Oncol Rep. 2006 Feb;15(2):311-5 [16391847.001]
  • [Cites] Curr Opin Genet Dev. 2006 Feb;16(1):51-9 [16377174.001]
  • [Cites] J Invest Dermatol. 2006 Mar;126(3):621-7 [16410791.001]
  • [Cites] Exp Cell Res. 2006 Mar 10;312(5):659-67 [16256984.001]
  • [Cites] Sci STKE. 2006 May 16;2006(335):re4 [16705130.001]
  • [Cites] J Microbiol. 2006 Apr;44(2):217-25 [16728959.001]
  • [Cites] Histochem Cell Biol. 2006 Jul;126(1):17-26 [16416023.001]
  • [Cites] Am J Pathol. 2006 Jul;169(1):314-24 [16816383.001]
  • [Cites] J Virol. 2007 Mar;81(5):2117-27 [17166914.001]
  • [Cites] Cancer Cell. 2007 Mar;11(3):245-58 [17349582.001]
  • [Cites] Nat Rev Immunol. 2007 May;7(5):391-401 [17457345.001]
  • [Cites] J Virol. 2007 May;81(10):5079-90 [17329329.001]
  • [Cites] J Cell Biol. 2007 May 21;177(4):613-24 [17502423.001]
  • [Cites] J Virol. 2008 Apr;82(8):4184-9 [18272573.001]
  • [Cites] Blood. 1994 Oct 15;84(8):2711-20 [7522639.001]
  • [Cites] J Immunol. 1994 Nov 15;153(10):4816-25 [7963547.001]
  • [Cites] Cancer Surv. 1995;24:129-40 [7553658.001]
  • [Cites] J Clin Pathol. 1995 Nov;48(11):1011-6 [8543622.001]
  • [Cites] Res Virol. 1996 Sep-Oct;147(5):267-75 [8880996.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14862-7 [8962146.001]
  • [Cites] J Virol. 1997 Mar;71(3):1963-74 [9032328.001]
  • [Cites] Am J Pathol. 1997 Mar;150(3):929-38 [9060831.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 3;95(5):2509-14 [9482916.001]
  • [Cites] J Cell Biol. 1998 Mar 23;140(6):1475-84 [9508779.001]
  • [Cites] J Virol. 1999 Mar;73(3):2232-42 [9971806.001]
  • [Cites] J Virol. 1999 Aug;73(8):6892-902 [10400787.001]
  • [Cites] Nat Med. 1999 Sep;5(9):1039-43 [10470081.001]
  • [Cites] Trends Cell Biol. 2004 Nov;14(11):589-93 [15519846.001]
  • [Cites] Mol Cell Biol. 2005 Jan;25(1):389-402 [15601859.001]
  • [Cites] J Biol Chem. 2005 Apr 1;280(13):12758-65 [15695815.001]
  • [Cites] Am J Pathol. 2005 May;166(5):1515-22 [15855650.001]
  • [Cites] J Clin Invest. 2005 May;115(5):1369-78 [15864354.001]
  • [Cites] Traffic. 2005 Jun;6(6):429-41 [15882441.001]
  • [Cites] J Virol. 2000 Jun;74(11):5300-9 [10799607.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):8051-6 [10859362.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jul 18;97(15):8455-60 [10890918.001]
  • [Cites] Exp Cell Res. 2000 Aug 25;259(1):158-66 [10942588.001]
  • [Cites] Adv Cancer Res. 2001;80:51-82 [11034540.001]
  • [Cites] J Investig Dermatol Symp Proc. 2000 Dec;5(1):10-3 [11147668.001]
  • [Cites] J Gen Virol. 2001 May;82(Pt 5):1175-80 [11297692.001]
  • [Cites] J Clin Invest. 2001 Jun;107(12):1599-606 [11413168.001]
  • [Cites] Eur J Cancer. 2001 Jul;37(10):1251-69 [11423257.001]
  • [Cites] Oncogene. 2001 Jun 7;20(26):3323-31 [11423982.001]
  • [Cites] Thromb Haemost. 2001 Jul;86(1):308-15 [11487019.001]
  • [Cites] Immunity. 2001 Oct;15(4):627-36 [11672544.001]
  • [Cites] J Virol. 2002 Mar;76(6):2912-23 [11861858.001]
  • [Cites] Anal Chem. 2002 Mar 15;74(6):1333-9 [11924593.001]
  • [Cites] Infect Immun. 2002 May;70(5):2605-13 [11953402.001]
  • [Cites] Genes Dev. 2002 Aug 1;16(15):1977-89 [12154127.001]
  • [Cites] Virus Res. 2002 Dec;90(1-2):77-89 [12457964.001]
  • [Cites] Trends Cell Biol. 2003 Jan;13(1):7-12 [12480335.001]
  • [Cites] Cell Commun Adhes. 2002 Mar-Apr;9(2):103-15 [12487411.001]
  • [Cites] J Virol. 2003 Jan;77(2):1427-40 [12502858.001]
  • (PMID = 18667499.001).
  • [ISSN] 1098-5514
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / T32 AI07472; United States / NIAID NIH HHS / AI / R01 CA/AI 094011; United States / NCRR NIH HHS / RR / P51 RR000163; United States / NCI NIH HHS / CA / R01 CA094011-04; United States / NCI NIH HHS / CA / R01 CA99906; United States / NCRR NIH HHS / RR / P51 RR000163-496078; United States / NCI NIH HHS / CA / R01 CA099906; United States / NIAID NIH HHS / AI / T32 AI007472; United States / NCRR NIH HHS / RR / RR000163-496078; United States / NCI NIH HHS / CA / R01 CA094011; United States / NCI NIH HHS / CA / CA094011-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Catenins; 0 / Ubiquitin
  • [Other-IDs] NLM/ PMC2546942
  •  go-up   go-down


2. West J, Damania B: Upregulation of the TLR3 pathway by Kaposi's sarcoma-associated herpesvirus during primary infection. J Virol; 2008 Jun;82(11):5440-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Upregulation of the TLR3 pathway by Kaposi's sarcoma-associated herpesvirus during primary infection.
  • Kaposi's sarcoma-associated herpesvirus (KSHV) is associated with several different human malignancies, including Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 2006 Nov 15;177(10):7094-102 [17082626.001]
  • [Cites] J Immunol. 2006 Dec 1;177(11):7505-9 [17114417.001]
  • [Cites] Glia. 2007 Feb;55(3):239-52 [17091495.001]
  • [Cites] J Vasc Res. 2007;44(1):51-60 [17167270.001]
  • [Cites] FASEB J. 2006 Oct;20(12):2153-5 [16935934.001]
  • [Cites] J Neuroimmunol. 2006 Oct;179(1-2):46-52 [16884784.001]
  • [Cites] J Biol Chem. 2000 Feb 18;275(7):4670-8 [10671496.001]
  • [Cites] Leuk Lymphoma. 2000 Jul;38(3-4):363-71 [10830743.001]
  • [Cites] Science. 2000 Jun 30;288(5475):2373-6 [10875924.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2001 Jan;280(1):L18-29 [11133491.001]
  • [Cites] Nature. 2000 Dec 7;408(6813):740-5 [11130078.001]
  • [Cites] Nat Immunol. 2001 Aug;2(8):675-80 [11477402.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):9237-42 [11470918.001]
  • [Cites] Nature. 2001 Oct 18;413(6857):732-8 [11607032.001]
  • [Cites] Clin Microbiol Rev. 2002 Jul;15(3):439-64 [12097251.001]
  • [Cites] Immunol Lett. 2003 Jan 22;85(2):85-95 [12527213.001]
  • [Cites] J Virol. 2003 Apr;77(8):4588-96 [12663765.001]
  • [Cites] J Virol. 2003 Jul;77(14):7978-90 [12829837.001]
  • [Cites] J Virol. 2003 Aug;77(15):8532-40 [12857922.001]
  • [Cites] Science. 2003 Aug 1;301(5633):640-3 [12855817.001]
  • [Cites] Nature. 2003 Aug 14;424(6950):743-8 [12872135.001]
  • [Cites] Trends Immunol. 2003 Oct;24(10):528-33 [14552836.001]
  • [Cites] Scand J Infect Dis. 2003;35(9):555-62 [14620134.001]
  • [Cites] Am J Pathol. 2003 Dec;163(6):2179-84 [14633592.001]
  • [Cites] J Virol. 2004 Apr;78(7):3601-20 [15016882.001]
  • [Cites] J Biol Chem. 2004 Mar 26;279(13):12542-50 [14729660.001]
  • [Cites] J Immunol. 2004 Jun 1;172(11):6545-9 [15153468.001]
  • [Cites] Cell Biochem Biophys. 2004;40(3):305-22 [15211030.001]
  • [Cites] Nat Rev Immunol. 2004 Jul;4(7):499-511 [15229469.001]
  • [Cites] Virology. 2004 Aug 1;325(2):225-40 [15246263.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Clin Infect Dis. 1992 Feb;14(2):555-67 [1313312.001]
  • [Cites] J Exp Med. 1993 Jun 1;177(6):1809-14 [8496693.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):3652-6 [8170963.001]
  • [Cites] J Biol Chem. 2007 Feb 9;282(6):3423-7 [17178723.001]
  • [Cites] Clin Exp Immunol. 2007 Mar;147(3):497-503 [17302899.001]
  • [Cites] J Virol. 2007 Sep;81(18):9748-58 [17609264.001]
  • [Cites] Science. 2007 Sep 14;317(5844):1522-7 [17872438.001]
  • [Cites] FASEB J. 1994 Oct;8(13):1055-60 [7926371.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] J Immunol. 1995 Dec 15;155(12):5769-76 [7499865.001]
  • [Cites] Blood. 1996 Feb 15;87(4):1423-31 [8608232.001]
  • [Cites] Science. 1996 Dec 6;274(5293):1739-44 [8939871.001]
  • [Cites] J Virol. 1997 Oct;71(10):7963-8 [9311888.001]
  • [Cites] Blood. 1997 Nov 15;90(10):4099-105 [9354680.001]
  • [Cites] J Gen Virol. 1998 Jul;79 ( Pt 7):1573-91 [9680119.001]
  • [Cites] Ann N Y Acad Sci. 1960 May 12;85:970-9 [13720072.001]
  • [Cites] Nat Struct Mol Biol. 2004 Nov;11(11):1060-7 [15502848.001]
  • [Cites] Nat Med. 2004 Dec;10(12):1366-73 [15558055.001]
  • [Cites] J Immunol. 2005 Jan 15;174(2):992-1002 [15634923.001]
  • [Cites] J Neuroimmunol. 2005 Feb;159(1-2):12-9 [15652398.001]
  • [Cites] J Immunol. 2005 Feb 1;174(3):1507-12 [15661910.001]
  • [Cites] J Biol Chem. 2005 Feb 18;280(7):5571-80 [15579900.001]
  • [Cites] J Virol. 2005 Mar;79(6):3350-7 [15731229.001]
  • [Cites] Cytokine Growth Factor Rev. 2005 Feb;16(1):1-14 [15733829.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Apr 12;102(15):5570-5 [15800047.001]
  • [Cites] J Immunol. 2005 Jul 1;175(1):376-84 [15972671.001]
  • [Cites] J Virol. 2005 Jul;79(14):9301-5 [15994824.001]
  • [Cites] J Virol. 2005 Aug;79(16):10138-46 [16051806.001]
  • [Cites] Blood. 2005 Oct 15;106(8):2790-7 [15976177.001]
  • [Cites] J Immunol. 2005 Oct 15;175(8):5314-23 [16210637.001]
  • [Cites] Glia. 2006 Feb;53(3):248-56 [16265667.001]
  • [Cites] Immunology. 2006 Jan;117(1):11-21 [16423036.001]
  • [Cites] J Immunol. 2006 Feb 1;176(3):1741-9 [16424204.001]
  • [Cites] Nat Immunol. 2006 Feb;7(2):131-7 [16424890.001]
  • [Cites] Virology. 2006 May 10;348(2):309-27 [16546233.001]
  • [Cites] J Gen Virol. 2006 Jul;87(Pt 7):1781-804 [16760382.001]
  • [Cites] J Gen Virol. 2006 Aug;87(Pt 8):2161-9 [16847112.001]
  • (PMID = 18367536.001).
  • [ISSN] 1098-5514
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA109232-05; United States / NCI NIH HHS / CA / R01 CA109232; United States / NIAID NIH HHS / AI / T32 AI007001; United States / NIDCR NIH HHS / DE / R01 DE018304-02; United States / NCI NIH HHS / CA / CA109232-03; United States / NIDCR NIH HHS / DE / R01-DE018281; United States / NCI NIH HHS / CA / CA109232-01; United States / NIDCR NIH HHS / DE / DE018304-01; United States / NIDCR NIH HHS / DE / R01-DE018304; United States / NIDCR NIH HHS / DE / R01 DE018304; United States / NCI NIH HHS / CA / CA109232-02; United States / NIAID NIH HHS / AI / T32AI007001; United States / NCI NIH HHS / CA / R01 CA109232-05; United States / NCI NIH HHS / CA / R01 CA109232-02; United States / NIDCR NIH HHS / DE / R01 DE018304-01; United States / PHS HHS / / R01-SCA096500; United States / NIDCR NIH HHS / DE / R01 DE018304-03; United States / NIDCR NIH HHS / DE / DE018304-02; United States / NCI NIH HHS / CA / R01 CA109232-01; United States / NCI NIH HHS / CA / R01 CA109232-03; United States / NIDCR NIH HHS / DE / DE018304-03; United States / NIDCR NIH HHS / DE / R01 DE018281
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines; 0 / Intercellular Signaling Peptides and Proteins; 0 / Interferon Regulatory Factor-1; 0 / NF-kappa B; 0 / RNA, Small Interfering; 0 / Toll-Like Receptor 3
  • [Other-IDs] NLM/ PMC2395190
  •  go-up   go-down


3. Bu W, Carroll KD, Palmeri D, Lukac DM: Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 ORF50/Rta lytic switch protein functions as a tetramer. J Virol; 2007 Jun;81(11):5788-806
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 ORF50/Rta lytic switch protein functions as a tetramer.
  • The Kaposi's sarcoma-associated herpesvirus open reading frame 50 (ORF50) protein (called Rta), is necessary and sufficient for reactivation of the virus from latency.
  • [MeSH-major] Herpesvirus 8, Human / chemistry. Immediate-Early Proteins / chemistry. Protein Structure, Quaternary. Sarcoma, Kaposi / virology. Trans-Activators / chemistry. Viral Proteins / chemistry. Virus Activation

  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. (L)-PROLINE .
  • Hazardous Substances Data Bank. L-Leucine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Virol. 2005 Mar;79(6):3479-87 [15731242.001]
  • [Cites] J Virol. 2005 May;79(9):5640-52 [15827179.001]
  • [Cites] J Virol. 2005 Jul;79(14):8750-63 [15994769.001]
  • [Cites] Oncogene. 2005 Sep 8;24(40):6165-73 [15897867.001]
  • [Cites] Dermatology. 2001;203(1):19-23 [11549794.001]
  • [Cites] Arch Virol. 2001 Jul;146(7):1415-26 [11556717.001]
  • [Cites] J Invest Dermatol. 2001 Oct;117(4):858-63 [11676823.001]
  • [Cites] J Virol. 2001 Dec;75(24):11961-73 [11711586.001]
  • [Cites] J Virol. 2002 Mar;76(6):2634-40 [11861829.001]
  • [Cites] J Virol. 2002 Apr;76(7):3168-78 [11884541.001]
  • [Cites] J Virol. 2002 May;76(10):5000-13 [11967316.001]
  • [Cites] J Virol. 2002 Jun;76(12):6213-23 [12021355.001]
  • [Cites] J Infect Dis. 2002 Jun 15;185(12):1736-44 [12085319.001]
  • [Cites] J Virol. 2002 Aug;76(16):8252-64 [12134031.001]
  • [Cites] Genes Dev. 2002 Aug 1;16(15):1977-89 [12154127.001]
  • [Cites] Mol Cell Biol. 2002 Sep;22(18):6321-35 [12192032.001]
  • [Cites] Eur J Immunol. 2002 Oct;32(10):2711-20 [12355422.001]
  • [Cites] Mol Cell Biol. 2003 Nov;23(22):8282-94 [14585985.001]
  • [Cites] Blood. 2004 Mar 1;103(5):1632-4 [14615380.001]
  • [Cites] J Virol. 2004 Apr;78(8):4248-67 [15047839.001]
  • [Cites] AIDS. 2004 Feb 20;18(3):485-93 [15090801.001]
  • [Cites] J Virol. 2004 May;78(10):5491-9 [15113928.001]
  • [Cites] J Virol. 2004 Jul;78(13):6818-26 [15194757.001]
  • [Cites] Virology. 1999 Oct 25;263(2):436-49 [10544116.001]
  • [Cites] Cancer. 2004 Jun 15;100(12):2644-54 [15197808.001]
  • [Cites] J Virol. 2004 Aug;78(16):8615-29 [15280471.001]
  • [Cites] J Virol. 2004 Oct;78(19):10657-73 [15367633.001]
  • [Cites] Biopolymers. 1987 Sep;26(9):1587-600 [3663874.001]
  • [Cites] J Mol Biol. 1988 Jun 5;201(3):601-19 [3418712.001]
  • [Cites] Science. 1989 Jan 27;243(4890):538-42 [2911757.001]
  • [Cites] Science. 1990 Aug 24;249(4971):912-5 [2144057.001]
  • [Cites] Science. 1990 Nov 2;250(4981):646-51 [2237415.001]
  • [Cites] Science. 1990 Dec 7;250(4986):1400-3 [2147779.001]
  • [Cites] FEBS Lett. 1990 Dec 17;277(1-2):185-8 [2269352.001]
  • [Cites] J Mol Biol. 1991 Mar 20;218(2):397-412 [2010917.001]
  • [Cites] Nucleic Acids Res. 1991 May 25;19(10):2661-7 [1645863.001]
  • [Cites] Science. 1991 Oct 25;254(5031):539-44 [1948029.001]
  • [Cites] Pept Res. 1990 May-Jun;3(3):123-37 [2134057.001]
  • [Cites] Biochemistry. 1992 Jun 30;31(25):5739-46 [1610823.001]
  • [Cites] Pept Res. 1988 Sep-Oct;1(1):19-30 [2980779.001]
  • [Cites] Genes Dev. 1993 Sep;7(9):1810-23 [8370528.001]
  • [Cites] Biochem J. 1994 Jan 15;297 ( Pt 2):249-60 [8297327.001]
  • [Cites] J Mol Biol. 1994 Apr 8;237(4):500-12 [8151708.001]
  • [Cites] Cell Mol Life Sci. 2005 Dec;62(23):2771-91 [16231091.001]
  • [Cites] EMBO Rep. 2006 Jan;7(1):41-5 [16391536.001]
  • [Cites] Bioinformatics. 2006 Feb 1;22(3):356-8 [16317077.001]
  • [Cites] J Virol. 2006 Mar;80(6):2958-67 [16501105.001]
  • [Cites] J Virol. 2006 Oct;80(19):9697-709 [16973574.001]
  • [Cites] J Virol. 2006 Dec;80(24):12171-86 [17020951.001]
  • [Cites] J Exp Med. 2000 Feb 7;191(3):417-22 [10662787.001]
  • [Cites] J Virol. 2000 Apr;74(8):3586-97 [10729134.001]
  • [Cites] J Virol. 2000 Jul;74(13):6207-12 [10846108.001]
  • [Cites] J Clin Virol. 2000 Aug;17(2):127-36 [10942093.001]
  • [Cites] J Virol. 2000 Sep;74(18):8623-34 [10954564.001]
  • [Cites] J Acquir Immune Defic Syndr. 2000 Jul 1;24(3):270-4 [10969352.001]
  • [Cites] AIDS. 2000 Sep 29;14(14):2109-16 [11061651.001]
  • [Cites] Semin Cancer Biol. 2000 Oct;10(5):367-81 [11100885.001]
  • [Cites] J Virol. 2001 Jan;75(2):891-902 [11134302.001]
  • [Cites] Cell Mol Life Sci. 1999 Nov 30;56(9-10):788-806 [11212339.001]
  • [Cites] J Natl Cancer Inst Monogr. 2001;(28):44-9 [11158206.001]
  • [Cites] J Virol. 2001 Feb;75(4):1909-17 [11160690.001]
  • [Cites] J Virol. 2001 Mar;75(6):2810-7 [11222705.001]
  • [Cites] J Virol. 2001 Apr;75(7):3129-40 [11238840.001]
  • [Cites] J Virol. 2001 Apr;75(7):3175-84 [11238844.001]
  • [Cites] J Virol. 2001 May;75(10):4843-53 [11312356.001]
  • [Cites] J Virol. 2001 Jul;75(13):5891-8 [11390590.001]
  • [Cites] J Virol. 2001 Aug;75(15):6786-99 [11435557.001]
  • [Cites] J Virol. 2001 Aug;75(15):6894-900 [11435569.001]
  • [Cites] Anal Biochem. 1994 Mar;217(2):220-30 [8203750.001]
  • [Cites] Science. 1994 Jul 15;265(5170):386-91 [8023159.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] Science. 1995 Feb 24;267(5201):1078-9 [7855583.001]
  • [Cites] Science. 1995 Mar 10;267(5203):1498-502 [7878469.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]
  • [Cites] Science. 1995 Apr 28;268(5210):582-3 [7725108.001]
  • [Cites] Lancet. 1995 Sep 23;346(8978):799-802 [7674745.001]
  • [Cites] Protein Sci. 1995 Aug;4(8):1596-607 [8520486.001]
  • [Cites] Cancer Res. 1996 Jan 1;56(1):158-63 [8548757.001]
  • [Cites] Blood. 1996 Jul 15;88(2):645-56 [8695812.001]
  • [Cites] Nat Med. 1996 Aug;2(8):918-24 [8705863.001]
  • [Cites] Nat Med. 1996 Aug;2(8):925-8 [8705864.001]
  • [Cites] Lancet. 1996 Oct 26;348(9035):1133-8 [8888167.001]
  • [Cites] J Biol Chem. 1997 May 2;272(18):11718-22 [9115224.001]
  • [Cites] J Mol Biol. 1997 Oct 17;273(1):61-74 [9367746.001]
  • [Cites] J Virol. 1998 Feb;72(2):1005-12 [9444993.001]
  • [Cites] AIDS. 1998 May 7;12(7):F45-9 [9619797.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10437-42 [9724721.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10866-71 [9724796.001]
  • [Cites] Virology. 1998 Dec 20;252(2):304-12 [9878608.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1999 Jan 1;20(1):34-8 [9928727.001]
  • [Cites] N Engl J Med. 1999 Apr 8;340(14):1063-70 [10194235.001]
  • [Cites] J Virol. 1999 Jul;73(7):6006-14 [10364352.001]
  • [Cites] J Virol. 1999 Nov;73(11):9348-61 [10516043.001]
  • [Cites] J Virol. 2004 Dec;78(24):13637-52 [15564474.001]
  • [Cites] Immunity. 2005 Jan;22(1):59-70 [15664159.001]
  • [Cites] J Virol. 2005 Feb;79(4):2420-31 [15681443.001]
  • [Cites] Virology. 2007 Mar 1;359(1):19-27 [17055026.001]
  • [Cites] J Virol. 2002 Dec;76(23):12044-54 [12414946.001]
  • [Cites] J Virol. 2002 Dec;76(24):12574-83 [12438583.001]
  • [Cites] J Virol. 2003 Jan;77(1):600-23 [12477864.001]
  • [Cites] Mol Cell Biol. 2003 Mar;23(6):2055-67 [12612078.001]
  • [Cites] Microbiol Mol Biol Rev. 2003 Jun;67(2):175-212, table of contents [12794189.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8490-5 [12832621.001]
  • [Cites] AIDS. 2003 Aug 15;17(12):1847-51 [12891072.001]
  • [Cites] J Virol. 2003 Sep;77(17):9399-411 [12915555.001]
  • [Cites] J Virol. 2003 Sep;77(17):9451-62 [12915560.001]
  • [Cites] J Virol. 2003 Sep;77(17):9590-612 [12915572.001]
  • (PMID = 17392367.001).
  • [ISSN] 0022-538X
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immediate-Early Proteins; 0 / ORF 50 transactivator; 0 / Rta protein, Human herpesvirus 8; 0 / Trans-Activators; 0 / Viral Proteins; 9DLQ4CIU6V / Proline; GMW67QNF9C / Leucine
  • [Other-IDs] NLM/ PMC1900300
  •  go-up   go-down


Advertisement
4. Sánchez del Monte J, Hernández Guerrero A, Sobrino Cossio S, Lárraga Octavio A, Sánchez Benítez G, López Blanco P, Elguero Pineda E: [Clinical manifestations and endoscopic characteristics of Kaposi's sarcoma in patients with acquired immunodeficiency syndrome]. Rev Gastroenterol Mex; 2005 Oct-Dec;70(4):416-23
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical manifestations and endoscopic characteristics of Kaposi's sarcoma in patients with acquired immunodeficiency syndrome].
  • [Transliterated title] Manifestaciones clinicas y características endoscópicas del sarcoma de Kaposi en pacientes con síndrome de inmunodeficiencia adquirida.
  • BACKGROUND: Kaposi sarcoma may be the initial manifestation of immunodeficiency acquired syndrome (AIDS )in 30% of patients.
  • METHOD: 12 consecutive cases with AIDS and Kaposi sarcoma.
  • The distribution of Kaposi sarcoma was as follows: hard palate 7, soft palate 2, larynx 3, esophagus 2, stomach 10, duodenum 2, colon 5 and anal conduct 1.
  • The biopsy was positive to Kaposi sarcoma in at least one lesion of each patient.
  • CONCLUSIONS: The Kaposi sarcoma appears as a multiple lesion with diverse aspect and colors that go from purple to blue or red.
  • There is correlation between a high number of Kaposi sarcoma lesions, affected organs, immunologic status and mortality.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Gastrointestinal Neoplasms / etiology. Sarcoma, Kaposi / etiology

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17058981.001).
  • [ISSN] 0375-0906
  • [Journal-full-title] Revista de gastroenterología de México
  • [ISO-abbreviation] Rev Gastroenterol Mex
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


5. Cuffy M, Abir F, Longo WE: Management of less common tumors of the colon, rectum, and anus. Clin Colorectal Cancer; 2006 Jan;5(5):327-37
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of less common tumors of the colon, rectum, and anus.
  • The majority of colorectal and anal malignancies are adenocarcinomas and squamous cell cancers, respectively.
  • Despite the predominance of these neoplasms in these locations, rare histiotypes of the colon, rectum, and anus do occur.
  • These histotypes include but are not limited to lymphoma, melanoma, diffuse cavernous hemangioma, and sarcomas, such as leiomyosarcoma or Kaposi's sarcoma.
  • A Medline search using "colon," "rectum,""anus," "lymphoma," "melanoma," "diffuse cavernous hemangioma," "squamous cell carcinoma," "carcinoid," "sarcoma," "leiomyosarcoma," "Kaposi's sarcoma," "Paget's disease," "Bowen's disease," and "basal cell carcinoma" as key words was performed as well as a cross-referencing of the bibliography cited in each work.
  • Rare tumors of the colon, rectum, and anus present diagnostic and management dilemmas for clinicians.
  • For uncommon anal lesions, such as Bowen's disease, Paget's disease, and basal cell carcinoma, wide local excision (WLE) with negative margins is the standard of care.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Colonic Neoplasms / therapy. Hemangioma, Cavernous / therapy. Lymphoma / therapy. Neuroendocrine Tumors / therapy. Rectal Neoplasms / therapy. Sarcoma / therapy

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16512991.001).
  • [ISSN] 1533-0028
  • [Journal-full-title] Clinical colorectal cancer
  • [ISO-abbreviation] Clin Colorectal Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 164
  •  go-up   go-down


6. Rivero Fernández M, García Martos M, Sanz Moya P, Vázquez Romero M, Fernández Amago MT, García Benayas MT, Sánchez-Pobre Bejarano P: [Kaposi's sarcoma with colorectal and anal canal involvement]. Gastroenterol Hepatol; 2010 Aug-Sep;33(7):508-11
MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Kaposi's sarcoma with colorectal and anal canal involvement].
  • [Transliterated title] Sarcoma de Kaposi con afectación colorrectal y del canal anal.
  • Kaposi's sarcoma (KS) is a low-grade vascular tumor, with four main variants, one of which is fairly prevalent in HIV-infected patients.
  • The gastrointestinal tract is involved in 40% of patients, but rectal and anal canal involvement is exceptional.
  • We report the case of a 39-year-old HIV-infected man with an unusual presentation of KS with colorectal and anal canal involvement in the absence of cutaneous disease.
  • [MeSH-major] Anus Neoplasms. Colorectal Neoplasms. Neoplasms, Multiple Primary. Sarcoma, Kaposi

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] .
  • (PMID = 20630624.001).
  • [ISSN] 0210-5705
  • [Journal-full-title] Gastroenterología y hepatología
  • [ISO-abbreviation] Gastroenterol Hepatol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


7. Carroll KD, Bu W, Palmeri D, Spadavecchia S, Lynch SJ, Marras SA, Tyagi S, Lukac DM: Kaposi's Sarcoma-associated herpesvirus lytic switch protein stimulates DNA binding of RBP-Jk/CSL to activate the Notch pathway. J Virol; 2006 Oct;80(19):9697-709
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Kaposi's Sarcoma-associated herpesvirus lytic switch protein stimulates DNA binding of RBP-Jk/CSL to activate the Notch pathway.
  • Kaposi's sarcoma-associated herpesvirus (KSHV) lytic switch protein, Rta, is a ligand-independent inducer of the Notch signal transduction pathway, and KSHV cannot reactivate from latency in cells null for the Notch target protein RBP-Jk.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nucleic Acids Res. 1994 Aug 11;22(15):2938-44 [8065905.001]
  • [Cites] J Virol. 1995 Jan;69(1):253-62 [7983717.001]
  • [Cites] J Virol. 1995 Mar;69(3):1944-50 [7853539.001]
  • [Cites] Science. 1995 Apr 28;268(5210):560-3 [7725102.001]
  • [Cites] Lancet. 1995 Sep 23;346(8978):799-802 [7674745.001]
  • [Cites] Nature. 1995 Sep 28;377(6547):355-8 [7566092.001]
  • [Cites] Genes Dev. 1995 Nov 1;9(21):2598-608 [7590238.001]
  • [Cites] Mol Cell Biol. 1996 Mar;16(3):952-9 [8622698.001]
  • [Cites] Development. 2004 Mar;131(5):965-73 [14973298.001]
  • [Cites] J Virol. 2004 Apr;78(8):3941-52 [15047810.001]
  • [Cites] J Virol. 2004 Apr;78(8):4248-67 [15047839.001]
  • [Cites] Immunity. 2004 May;20(5):611-22 [15142529.001]
  • [Cites] J Virol. 2004 Jul;78(13):6818-26 [15194757.001]
  • [Cites] Semin Cancer Biol. 2004 Oct;14(5):317-9 [15288256.001]
  • [Cites] EMBO J. 2004 Sep 1;23(17):3441-51 [15297877.001]
  • [Cites] Science. 2004 Oct 8;306(5694):269-71 [15472075.001]
  • [Cites] J Virol. 1987 May;61(5):1310-7 [3033261.001]
  • [Cites] Gene Anal Tech. 1988 Mar-Apr;5(2):22-31 [3192155.001]
  • [Cites] Nature. 1989 Aug 3;340(6232):393-7 [2547164.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Dec;86(23):9558-62 [2556717.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Oct;87(19):7390-4 [2170976.001]
  • [Cites] J Virol. 1991 May;65(5):2164-9 [1850003.001]
  • [Cites] J Virol. 1991 May;65(5):2545-54 [1850028.001]
  • [Cites] J Virol. 1991 Aug;65(8):4101-6 [1649318.001]
  • [Cites] Annu Rev Immunol. 2005;23:945-74 [15771590.001]
  • [Cites] J Virol. 2005 May;79(9):5640-52 [15827179.001]
  • [Cites] J Virol. 2005 Jul;79(14):8750-63 [15994769.001]
  • [Cites] Cancer Cell. 2005 Jul;8(1):13-23 [16023595.001]
  • [Cites] Oncogene. 2005 Sep 22;24(42):6333-44 [15940249.001]
  • [Cites] J Virol. 2005 Nov;79(22):14371-82 [16254371.001]
  • [Cites] FEBS Lett. 1996 Oct 21;395(2-3):221-4 [8898100.001]
  • [Cites] J Virol. 2000 Feb;74(4):1939-47 [10644367.001]
  • [Cites] Mol Cell Biol. 2000 Apr;20(7):2400-10 [10713164.001]
  • [Cites] J Biol Chem. 2000 Jun 2;275(22):17211-20 [10747963.001]
  • [Cites] Genes Dev. 2000 Jun 1;14(11):1343-52 [10837027.001]
  • [Cites] J Virol. 2000 Jul;74(13):6207-12 [10846108.001]
  • [Cites] J Virol. 2000 Sep;74(18):8623-34 [10954564.001]
  • [Cites] Blood. 2000 Sep 1;96(5):1906-13 [10961893.001]
  • [Cites] Nat Genet. 2000 Dec;26(4):484-9 [11101851.001]
  • [Cites] J Virol Methods. 2001 Feb;91(2):109-17 [11164492.001]
  • [Cites] J Virol. 2001 Mar;75(5):2033-40 [11160707.001]
  • [Cites] J Virol. 2001 Jul;75(13):5899-912 [11390591.001]
  • [Cites] Development. 1996 May;122(5):1373-83 [8625826.001]
  • [Cites] J Exp Med. 1996 May 1;183(5):2283-91 [8642337.001]
  • [Cites] Genes Dev. 1996 Aug 1;10(15):1930-44 [8756350.001]
  • [Cites] J Clin Invest. 1997 May 1;99(9):2082-6 [9151779.001]
  • [Cites] Mol Cell Biol. 1997 Sep;17(9):5620-8 [9271437.001]
  • [Cites] Development. 1997 Oct;124(20):4133-41 [9374409.001]
  • [Cites] Mol Cell Biol. 1998 Jan;18(1):644-54 [9418910.001]
  • [Cites] Mol Cell Biol. 1998 Apr;18(4):2077-88 [9528780.001]
  • [Cites] Cell. 1998 May 15;93(4):649-60 [9604939.001]
  • [Cites] Nature. 1998 May 28;393(6683):382-6 [9620803.001]
  • [Cites] Genes Dev. 1998 Aug 1;12(15):2269-77 [9694793.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10866-71 [9724796.001]
  • [Cites] Leukemia. 1998 Oct;12(10):1507-17 [9766492.001]
  • [Cites] Genes Dev. 1998 Dec 1;12(23):3728-40 [9851979.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jan 5;96(1):23-8 [9874765.001]
  • [Cites] Virology. 1998 Dec 20;252(2):304-12 [9878608.001]
  • [Cites] N Engl J Med. 1999 Apr 8;340(14):1063-70 [10194235.001]
  • [Cites] Hum Mol Genet. 1999 May;8(5):723-30 [10196361.001]
  • [Cites] Dev Biol. 1999 Sep 1;213(1):33-53 [10452845.001]
  • [Cites] J Virol. 1999 Nov;73(11):9348-61 [10516043.001]
  • [Cites] Mol Cell. 2004 Nov 19;16(4):509-20 [15546612.001]
  • [Cites] Curr Opin Hematol. 2004 Nov;11(6):426-33 [15548998.001]
  • [Cites] Immunity. 2005 Jan;22(1):59-70 [15664159.001]
  • [Cites] J Virol. 2005 Mar;79(6):3468-78 [15731241.001]
  • [Cites] J Virol. 2005 Mar;79(6):3479-87 [15731242.001]
  • [Cites] Cancer Cell. 2003 Jun;3(6):551-64 [12842084.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8490-5 [12832621.001]
  • [Cites] J Virol. 2003 Sep;77(17):9399-411 [12915555.001]
  • [Cites] J Virol. 2003 Sep;77(17):9590-612 [12915572.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2004;44:219-38 [14744245.001]
  • [Cites] Mol Cell Biol. 2001 Jul;21(13):4337-46 [11390662.001]
  • [Cites] J Virol. 2001 Aug;75(15):6786-99 [11435557.001]
  • [Cites] J Virol. 2001 Aug;75(15):6894-900 [11435569.001]
  • [Cites] Mol Cell Biol. 2001 Sep;21(18):6222-32 [11509665.001]
  • [Cites] Semin Cancer Biol. 2001 Dec;11(6):423-34 [11669604.001]
  • [Cites] Differentiation. 2001 Dec;69(2-3):135-44 [11798067.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] J Virol. 2002 Apr;76(7):3168-78 [11884541.001]
  • [Cites] J Virol. 2002 May;76(10):5000-13 [11967316.001]
  • [Cites] Nat Immunol. 2002 May;3(5):443-50 [11967543.001]
  • [Cites] Mol Cell Biol. 2002 Jun;22(11):3927-41 [11997524.001]
  • [Cites] J Virol. 2002 Jun;76(12):6185-96 [12021352.001]
  • [Cites] Genes Dev. 2002 Jun 1;16(11):1397-411 [12050117.001]
  • [Cites] Dev Cell. 2002 Jul;3(1):127-36 [12110173.001]
  • [Cites] J Virol. 2002 Aug;76(16):8252-64 [12134031.001]
  • [Cites] Genes Dev. 2002 Aug 1;16(15):1977-89 [12154127.001]
  • [Cites] Blood. 2002 Sep 1;100(5):1919-21 [12176919.001]
  • [Cites] Mol Cell Biol. 2002 Nov;22(22):7812-9 [12391150.001]
  • [Cites] J Virol. 2002 Dec;76(23):12044-54 [12414946.001]
  • [Cites] Mol Cell Biol. 2003 Jan;23(1):14-25 [12482957.001]
  • [Cites] Methods Mol Biol. 2003;212:111-28 [12491906.001]
  • [Cites] Cancer Biol Ther. 2002 Sep-Oct;1(5):466-76 [12496471.001]
  • [Cites] Mol Cell Biol. 2003 Mar;23(6):2055-67 [12612078.001]
  • [Cites] J Biol Chem. 2003 Jun 6;278(23):21232-9 [12644465.001]
  • [Cites] Cell. 1991 Aug 23;66(4):649-61 [1831692.001]
  • [Cites] J Virol. 1991 Nov;65(11):5880-5 [1656076.001]
  • [Cites] J Virol. 1991 Dec;65(12):6765-71 [1658373.001]
  • [Cites] J Virol. 1992 May;66(5):2846-52 [1313905.001]
  • [Cites] J Virol. 2003 Jan;77(1):600-23 [12477864.001]
  • [Cites] EMBO J. 1993 Jan;12(1):167-75 [8381349.001]
  • [Cites] Genomics. 1993 Aug;17(2):306-15 [8406481.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Oct 15;90(20):9237-41 [8415684.001]
  • [Cites] Mol Cell Biol. 1994 May;14(5):3310-9 [8164682.001]
  • [Cites] J Virol. 1994 Aug;68(8):5184-93 [8035517.001]
  • (PMID = 16973574.001).
  • [ISSN] 0022-538X
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / Immediate-Early Proteins; 0 / Immunoglobulin J Recombination Signal Sequence-Binding Protein; 0 / Lectins; 0 / Receptors, Notch; 0 / Rta protein, Human herpesvirus 8; 0 / Trans-Activators; 0 / Viral Proteins; 0 / cerebellar soluble lectin
  • [Other-IDs] NLM/ PMC1617261
  •  go-up   go-down


8. Fujimuro M, Liu J, Zhu J, Yokosawa H, Hayward SD: Regulation of the interaction between glycogen synthase kinase 3 and the Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen. J Virol; 2005 Aug;79(16):10429-41
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regulation of the interaction between glycogen synthase kinase 3 and the Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen.
  • The Kaposi's sarcoma-associated herpesvirus (KSHV)-encoded latency-associated nuclear antigen (LANA) protein stabilizes beta-catenin by the novel mechanism of binding to the negative regulator, glycogen synthase kinase 3 (GSK-3), and depleting cytoplasmic GSK-3 levels.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Virol. 2004 Dec;78(24):14033-8 [15564510.001]
  • [Cites] J Biol Chem. 2003 Dec 5;278(49):48872-9 [14523002.001]
  • [Cites] Nat Med. 2000 Oct;6(10):1121-7 [11017143.001]
  • [Cites] J Gen Virol. 2000 Nov;81(Pt 11):2645-52 [11038375.001]
  • [Cites] J Virol. 2001 Apr;75(7):3250-8 [11238851.001]
  • [Cites] J Virol. 2001 Apr;75(8):3948-59 [11264383.001]
  • [Cites] Mol Cell. 2001 Jun;7(6):1321-7 [11430833.001]
  • [Cites] J Virol. 2001 Sep;75(17):7882-92 [11483733.001]
  • [Cites] J Biol Chem. 2001 Aug 17;276(33):31016-22 [11425857.001]
  • [Cites] J Biol Chem. 2001 Oct 5;276(40):37436-42 [11495916.001]
  • [Cites] Sci STKE. 2001 Sep 18;2001(100):re12 [11579232.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Oct;2(10):769-76 [11584304.001]
  • [Cites] J Biol Chem. 2001 Oct 19;276(42):39037-45 [11487578.001]
  • [Cites] J Biol Chem. 2002 Jan 18;277(3):2176-85 [11707456.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Feb 5;99(3):1182-7 [11818547.001]
  • [Cites] Virology. 2001 Dec 20;291(2):241-59 [11878894.001]
  • [Cites] EMBO J. 2002 Apr 2;21(7):1733-42 [11927557.001]
  • [Cites] J Biol Chem. 2002 May 3;277(18):16147-52 [11861647.001]
  • [Cites] Genes Dev. 2002 May 1;16(9):1066-76 [12000790.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):7951-5 [12048243.001]
  • [Cites] J Neurochem. 2002 Jun;81(5):1073-83 [12065620.001]
  • [Cites] J Biol Chem. 2002 Jun 28;277(26):23330-5 [11967263.001]
  • [Cites] J Biol Chem. 2002 Jul 26;277(30):27401-11 [12015325.001]
  • [Cites] J Virol. 2004 Jan;78(1):294-301 [14671111.001]
  • [Cites] Blood. 2004 Jan 1;103(1):222-8 [12969971.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15572-6 [14663138.001]
  • [Cites] J Biol Chem. 2004 Feb 13;279(7):5263-7 [14630927.001]
  • [Cites] Mol Cell Biol. 2004 Mar;24(5):2012-24 [14966281.001]
  • [Cites] J Virol. 2005 Feb;79(4):2637-42 [15681465.001]
  • [Cites] J Biol Chem. 2005 Feb 4;280(5):3862-74 [15525642.001]
  • [Cites] J Virol. 2005 Mar;79(6):3468-78 [15731241.001]
  • [Cites] J Virol. 2000 Oct;74(20):9637-45 [11000236.001]
  • [Cites] Virology. 1999 Nov 25;264(2):254-64 [10562490.001]
  • [Cites] Nature. 1999 Dec 23-30;402(6764):889-94 [10622254.001]
  • [Cites] J Virol. 2000 Sep;74(18):8532-40 [10954554.001]
  • [Cites] J Virol. 2002 Nov;76(22):11596-604 [12388720.001]
  • [Cites] J Virol. 2002 Nov;76(22):11677-87 [12388727.001]
  • [Cites] J Biol Chem. 2002 Nov 15;277(46):43844-8 [12223487.001]
  • [Cites] J Virol. 2002 Dec;76(24):12917-24 [12438617.001]
  • [Cites] J Virol. 2003 Feb;77(4):2779-83 [12552022.001]
  • [Cites] EMBO J. 2003 Feb 3;22(3):494-501 [12554650.001]
  • [Cites] Nat Med. 2003 Mar;9(3):300-6 [12592400.001]
  • [Cites] J Virol. 2003 May;77(10):5975-84 [12719589.001]
  • [Cites] J Gen Virol. 2003 Jun;84(Pt 6):1451-62 [12771414.001]
  • [Cites] J Virol. 2003 Jul;77(14):8019-30 [12829841.001]
  • [Cites] J Biol Chem. 2003 Aug 29;278(35):33067-77 [12796505.001]
  • [Cites] Genes Dev. 2003 Nov 15;17(22):2753-64 [14600025.001]
  • [Cites] Virology. 2004 Feb 20;319(2):225-36 [14980483.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):2882-7 [14981260.001]
  • [Cites] Trends Genet. 2004 Apr;20(4):177-81 [15041171.001]
  • [Cites] Trends Biochem Sci. 2004 Feb;29(2):95-102 [15102436.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5251-60 [15289331.001]
  • [Cites] Mol Cell. 2004 Aug 27;15(4):511-21 [15327768.001]
  • [Cites] J Virol. 2004 Sep;78(18):10074-85 [15331740.001]
  • [Cites] J Virol. 2004 Oct;78(19):10348-59 [15367601.001]
  • [Cites] Aging Cell. 2004 Oct;3(5):309-17 [15379854.001]
  • [Cites] J Virol. 2004 Nov;78(21):11648-55 [15479806.001]
  • [Cites] Biochem Soc Trans. 2004 Nov;32(Pt 5):803-8 [15494020.001]
  • [Cites] Anal Biochem. 1987 Nov 1;166(2):368-79 [2449095.001]
  • [Cites] Science. 1996 May 17;272(5264):1023-6 [8638126.001]
  • [Cites] Genes Dev. 1998 Nov 15;12(22):3499-511 [9832503.001]
  • [Cites] J Biol Chem. 1999 Apr 16;274(16):10681-4 [10196136.001]
  • [Cites] Science. 1999 Apr 23;284(5414):641-4 [10213686.001]
  • [Cites] Genes Dev. 1999 Jul 15;13(14):1768-73 [10421629.001]
  • [Cites] Mol Cell Biol. 1999 Oct;19(10):7147-57 [10490650.001]
  • (PMID = 16051835.001).
  • [ISSN] 0022-538X
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA085151; United States / NCI NIH HHS / CA / R01 CA85151
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Viral; 0 / Nuclear Proteins; 0 / latency-associated nuclear antigen; EC 2.7.11.26 / Glycogen Synthase Kinase 3
  • [Other-IDs] NLM/ PMC1182668
  •  go-up   go-down


9. Bower M, Palmieri C, Dhillon T: AIDS-related malignancies: changing epidemiology and the impact of highly active antiretroviral therapy. Curr Opin Infect Dis; 2006 Feb;19(1):14-9
MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE OF REVIEW: Three cancers in people with HIV denote an AIDS diagnosis: Kaposi's sarcoma, high-grade B-cell non-Hodgkin's lymphoma and invasive cervical cancer.
  • RECENT FINDINGS: The incidence of both Kaposi's sarcoma and non-Hodgkin's lymphoma has declined in the era of highly active antiretroviral therapy and the outcome of both tumours has improved.
  • Moreover, highly active antiretroviral therapy alone produces a response in a majority of antiretroviral-naïve patients with Kaposi's sarcoma.
  • In contrast, highly active antiretroviral therapy has had little impact on the incidence of human papilloma virus-associated tumours (cervical and anal cancer) in people with HIV, although it may improve survival by reducing opportunistic infection deaths.
  • SUMMARY: For those with access to highly active antiretroviral therapy, the good news from the AIDS-defining cancers - particularly Kaposi's sarcoma and non-Hodgkin's lymphoma - may be balanced by the increasing numbers of non AIDS-defining cancers.
  • [MeSH-minor] Female. Humans. Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / epidemiology. Sarcoma, Kaposi / drug therapy. Sarcoma, Kaposi / epidemiology. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / epidemiology

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16374212.001).
  • [ISSN] 0951-7375
  • [Journal-full-title] Current opinion in infectious diseases
  • [ISO-abbreviation] Curr. Opin. Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 45
  •  go-up   go-down


10. Lim ST, Levine AM: Non-AIDS-defining cancers and HIV infection. Curr HIV/AIDS Rep; 2005 Aug;2(3):146-53
MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Apart from Kaposi's sarcoma, non-Hodgkin's lymphoma, and cervical cancer, which are considered as AIDS-defining, several additional cancers, referred to as non-AIDS-defining cancers, are also statistically increased in HIV-infected persons.
  • These include Hodgkin's disease, anal carcinoma, lung cancer, nonmelanomatous skin cancer, and testicular germ cell tumors, among others.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Acquir Immune Defic Syndr. 2003 Apr 15;32(5):527-33 [12679705.001]
  • [Cites] Sex Transm Dis. 2004 Feb;31(2):96-9 [14743072.001]
  • [Cites] Eur J Epidemiol. 1995 Dec;11(6):609-14 [8861842.001]
  • [Cites] Ann Thorac Surg. 2003 Feb;75(2):367-71 [12607641.001]
  • [Cites] J Acquir Immune Defic Syndr. 2000 Aug 15;24(5):444-50 [11035615.001]
  • [Cites] Hematol Oncol Clin North Am. 1991 Apr;5(2):343-56 [2022598.001]
  • [Cites] Lancet. 1998 Jun 20;351(9119):1833-9 [9652666.001]
  • [Cites] J Natl Cancer Inst. 1997 Nov 5;89(21):1602-8 [9362158.001]
  • [Cites] AIDS. 2003 Feb 14;17(3):371-5 [12556691.001]
  • [Cites] AIDS Care. 1996 Feb;8(1):5-14 [8664369.001]
  • [Cites] Ann Oncol. 1993 Sep;4(8):635-41 [8240994.001]
  • [Cites] J Clin Oncol. 1995 Oct;13(10):2540-6 [7595705.001]
  • [Cites] Eur J Cancer. 2001 Jul;37(10):1276-87 [11423259.001]
  • [Cites] AIDS. 1998 Mar 26;12(5):495-503 [9543448.001]
  • [Cites] J Infect Dis. 1998 Feb;177(2):361-7 [9466522.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Apr 1;17(4):314-9 [9525431.001]
  • [Cites] JAMA. 1999 May 19;281(19):1822-9 [10340370.001]
  • [Cites] J Clin Oncol. 1995 Nov;13(11):2705-11 [7595728.001]
  • [Cites] Cancer. 2001 Dec 1;92(11):2739-45 [11753946.001]
  • [Cites] Int J STD AIDS. 2001 Feb;12(2):100-2 [11236097.001]
  • [Cites] J Natl Cancer Inst. 2000 Nov 15;92(22):1823-30 [11078759.001]
  • [Cites] Blood. 2002 Sep 15;100(6):1984-8 [12200356.001]
  • [Cites] Am J Med. 1985 Feb;78(2):211-5 [3918441.001]
  • [Cites] AIDS. 1999 May 7;13(7):839-43 [10357384.001]
  • [Cites] AIDS. 2001 Nov 9;15(16):2157-64 [11684935.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Aug 1;36(4):978-85 [15220706.001]
  • [Cites] JAMA. 2001 Apr 4;285(13):1736-45 [11277828.001]
  • [Cites] N Engl J Med. 1998 Mar 26;338(13):853-60 [9516219.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3447-53 [12972519.001]
  • [Cites] Cancer. 1992 Jul 15;70(2):432-6 [1617592.001]
  • [Cites] Cancer. 1990 May 15;65(10):2248-54 [2346909.001]
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1500-10 [10995805.001]
  • [Cites] Ann Oncol. 1999 Feb;10(2):189-95 [10093688.001]
  • [Cites] Cancer. 2000 Feb 1;88(3):563-9 [10649248.001]
  • [Cites] Ann Oncol. 2003 Oct;14(10):1562-9 [14504059.001]
  • [Cites] AIDS. 2002 May 24;16(8):1155-61 [12004274.001]
  • [Cites] Ann Intern Med. 2003 Mar 18;138(6):453-9 [12639077.001]
  • [Cites] J Clin Oncol. 1995 Jun;13(6):1391-7 [7538557.001]
  • [Cites] J Clin Oncol. 2004 Apr 1;22(7):1348-9; author reply 1349-50 [15051794.001]
  • [Cites] Clin Infect Dis. 2003 Jul 15;37(2):292-8 [12856222.001]
  • [Cites] Am J Med. 2000 Jun 1;108(8):634-41 [10856411.001]
  • [Cites] Semin Oncol. 2000 Aug;27(4):480-8 [10950375.001]
  • [Cites] Hematol Oncol Clin North Am. 1996 Oct;10(5):997-1010 [8880192.001]
  • [Cites] Br J Cancer. 1998 Oct;78(7):966-70 [9764592.001]
  • [Cites] Chest. 1993 Feb;103(2):410-3 [8432128.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1985 Sep;11(9):1587-93 [3928544.001]
  • [Cites] Blood. 1999 Apr 1;93(7):2319-26 [10090942.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Nov 7;97(23):12667-71 [11058153.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1101-5 [9169819.001]
  • [Cites] Chest. 1998 Jan;113(1):154-61 [9440583.001]
  • [Cites] Mutat Res. 1999 Oct 19;429(2):249-59 [10526209.001]
  • [Cites] Eur J Cancer. 2000 Apr;36(6):754-8 [10762748.001]
  • [Cites] J Clin Oncol. 2003 May 15;21(10):1922-7 [12743144.001]
  • [Cites] Fundam Appl Toxicol. 1996 Aug;32(2):148-58 [8921318.001]
  • [Cites] Mutagenesis. 2000 Sep;15(5):405-10 [10970446.001]
  • [Cites] Int J Cancer. 2001 Dec 1;94(5):753-7 [11745473.001]
  • [Cites] J Acquir Immune Defic Syndr. 2001 Dec 15;28(5):422-8 [11744829.001]
  • [Cites] Ann Oncol. 1991 Feb;2 Suppl 2:201-5 [1710920.001]
  • [Cites] Lung Cancer. 2002 Apr;36(1):9-14 [11891027.001]
  • [Cites] Br J Cancer. 2003 Aug 4;89(3):457-9 [12888811.001]
  • [Cites] Am J Surg Pathol. 1996 Dec;20(12):1520-4 [8944046.001]
  • [Cites] Chest. 1992 Dec;102(6):1704-8 [1446476.001]
  • (PMID = 16091262.001).
  • [ISSN] 1548-3568
  • [Journal-full-title] Current HIV/AIDS reports
  • [ISO-abbreviation] Curr HIV/AIDS Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 64
  •  go-up   go-down


11. Spadavecchia S, Gonzalez-Lopez O, Carroll KD, Palmeri D, Lukac DM: Convergence of Kaposi's sarcoma-associated herpesvirus reactivation with Epstein-Barr virus latency and cellular growth mediated by the notch signaling pathway in coinfected cells. J Virol; 2010 Oct;84(20):10488-500
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Convergence of Kaposi's sarcoma-associated herpesvirus reactivation with Epstein-Barr virus latency and cellular growth mediated by the notch signaling pathway in coinfected cells.
  • Kaposi's sarcoma-associated herpesvirus (KSHV) is the etiologic agent of primary effusion lymphoma (PEL).

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] EMBO J. 1997 Nov 3;16(21):6478-85 [9351829.001]
  • [Cites] Blood. 1998 Feb 1;91(3):747-55 [9446632.001]
  • [Cites] Mol Cell Biol. 1998 May;18(5):2835-44 [9566902.001]
  • [Cites] Oncogene. 1998 Apr 2;16(13):1731-42 [9582021.001]
  • [Cites] J Gen Virol. 1998 Jun;79 ( Pt 6):1445-52 [9634087.001]
  • [Cites] Dev Biol. 1999 Sep 1;213(1):33-53 [10452845.001]
  • [Cites] Virology. 1999 Sep 15;262(1):18-30 [10489337.001]
  • [Cites] J Virol. 1999 Nov;73(11):9348-61 [10516043.001]
  • [Cites] Science. 1999 Oct 8;286(5438):300-3 [10514374.001]
  • [Cites] J Virol. 2005 Mar;79(6):3479-87 [15731242.001]
  • [Cites] J Virol. 2005 Nov;79(22):14371-82 [16254371.001]
  • [Cites] Blood. 2006 Jan 1;107(1):277-84 [16150942.001]
  • [Cites] J Virol. 2006 Oct;80(19):9697-709 [16973574.001]
  • [Cites] Physiol Rev. 2007 Jan;87(1):99-163 [17237344.001]
  • [Cites] J Virol. 2007 Jun;81(11):6068-78 [17376914.001]
  • [Cites] J Virol. 2007 Jun;81(11):5788-806 [17392367.001]
  • [Cites] Anal Biochem. 2007 Jul 15;366(2):197-206 [17512890.001]
  • [Cites] J Virol. 2007 Aug;81(16):8451-67 [17537858.001]
  • [Cites] J Virol. 2007 Dec;81(24):13299-314 [17913801.001]
  • [Cites] PLoS One. 2008;3(2):e1569 [18253508.001]
  • [Cites] J Virol. 2008 Nov;82(21):10709-23 [18715905.001]
  • [Cites] J Virol. 2009 May;83(10):5014-27 [19264782.001]
  • [Cites] Dev Cell. 2009 May;16(5):633-47 [19460341.001]
  • [Cites] J Virol. 1999 Dec;73(12):10525-30 [10559372.001]
  • [Cites] Leuk Lymphoma. 2000 Jul;38(3-4):401-9 [10830748.001]
  • [Cites] J Virol. 2000 Nov;74(21):10187-93 [11024147.001]
  • [Cites] J Virol. 2001 Mar;75(5):2033-40 [11160707.001]
  • [Cites] J Biol Chem. 2001 Jan 12;276(2):1195-203 [11031256.001]
  • [Cites] J Virol. 2001 Apr;75(8):3537-46 [11264343.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10866-71 [9724796.001]
  • [Cites] Leukemia. 1998 Oct;12(10):1507-17 [9766492.001]
  • [Cites] Virology. 1998 Dec 20;252(2):304-12 [9878608.001]
  • [Cites] J Virol. 1999 Apr;73(4):2770-80 [10074124.001]
  • [Cites] J Biol Chem. 1999 Jun 4;274(23):16085-96 [10347160.001]
  • [Cites] J Virol. 2001 Jul;75(13):5899-912 [11390591.001]
  • [Cites] Genes Dev. 2002 Aug 1;16(15):1977-89 [12154127.001]
  • [Cites] J Biol Chem. 2003 Feb 7;278(6):3694-704 [12446712.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8490-5 [12832621.001]
  • [Cites] Blood. 2004 Jan 1;103(1):313-6 [12969959.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 6;101(1):141-6 [14691250.001]
  • [Cites] J Virol. 2004 Apr;78(8):3941-52 [15047810.001]
  • [Cites] Oncogene. 2004 Apr 8;23(15):2681-93 [14767477.001]
  • [Cites] J Exp Med. 1984 May 1;159(5):1554-9 [6325575.001]
  • [Cites] J Exp Med. 1990 Jul 1;172(1):61-8 [2162905.001]
  • [Cites] J Virol. 1992 Nov;66(11):6496-501 [1404600.001]
  • [Cites] J Biol Chem. 1992 Dec 5;267(34):24157-60 [1332946.001]
  • [Cites] J Exp Med. 1993 Mar 1;177(3):763-74 [8382256.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] EMBO J. 1995 Jan 3;14(1):88-96 [7828599.001]
  • [Cites] Oncogene. 1995 Feb 2;10(3):549-60 [7845680.001]
  • [Cites] Cell. 1995 Feb 10;80(3):389-99 [7859281.001]
  • [Cites] J Virol. 1995 May;69(5):2968-76 [7707523.001]
  • [Cites] Blood. 1995 Oct 1;86(7):2708-14 [7670109.001]
  • [Cites] Nature. 1995 Sep 28;377(6547):355-8 [7566092.001]
  • [Cites] J Virol. 1996 Jan;70(1):549-58 [8523568.001]
  • [Cites] EMBO J. 1996 Jan 15;15(2):375-82 [8617212.001]
  • [Cites] Nat Med. 1996 Mar;2(3):342-6 [8612236.001]
  • [Cites] Blood. 1996 Jul 15;88(2):645-56 [8695812.001]
  • [Cites] Nat Med. 1996 Aug;2(8):918-24 [8705863.001]
  • [Cites] Nat Med. 1996 Aug;2(8):925-8 [8705864.001]
  • [Cites] Br J Haematol. 1996 Sep;94(3):533-43 [8790156.001]
  • [Cites] Lancet. 1996 Oct 26;348(9035):1133-8 [8888167.001]
  • [Cites] Science. 1996 Dec 6;274(5293):1739-44 [8939871.001]
  • [Cites] Cytometry. 1996 Dec 1;25(4):333-40 [8946140.001]
  • [Cites] Oncogene. 1996 Nov 21;13(10):2243-54 [8950992.001]
  • [Cites] J Virol. 1997 Jan;71(1):314-24 [8985352.001]
  • [Cites] EMBO J. 1996 Dec 16;15(24):7070-8 [9003782.001]
  • [Cites] Blood. 1997 Aug 1;90(3):1186-91 [9242551.001]
  • [Cites] Development. 1997 Oct;124(20):4133-41 [9374409.001]
  • (PMID = 20686042.001).
  • [ISSN] 1098-5514
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / R01 AI078138; United States / NIAID NIH HHS / AI / AI 078138
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Culture Media, Conditioned; 0 / DNA Primers; 0 / EBNA-2 protein, Human herpesvirus 4; 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / Epstein-Barr Virus Nuclear Antigens; 0 / Immediate-Early Proteins; 0 / Immunoglobulin J Recombination Signal Sequence-Binding Protein; 0 / Receptors, Notch; 0 / Rta protein, Human herpesvirus 8; 0 / Trans-Activators; 0 / Viral Matrix Proteins; 0 / Viral Proteins
  • [Other-IDs] NLM/ PMC2950570
  •  go-up   go-down


12. Garrigues HJ, Rubinchikova YE, Dipersio CM, Rose TM: Integrin alphaVbeta3 Binds to the RGD motif of glycoprotein B of Kaposi's sarcoma-associated herpesvirus and functions as an RGD-dependent entry receptor. J Virol; 2008 Feb;82(3):1570-80
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Integrin alphaVbeta3 Binds to the RGD motif of glycoprotein B of Kaposi's sarcoma-associated herpesvirus and functions as an RGD-dependent entry receptor.
  • Kaposi's sarcoma-associated herpesvirus (KSHV) envelope-associated glycoprotein B (gB) is involved in the initial steps of binding to host cells during KSHV infection. gB contains an RGD motif reported to bind the integrin alpha(3)beta(1) during virus entry.

  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1997 May 1;57(9):1682-9 [9135008.001]
  • [Cites] J Biol Chem. 1997 Aug 8;272(32):19794-800 [9242639.001]
  • [Cites] Int J Biochem Cell Biol. 1997 May;29(5):721-5 [9251239.001]
  • [Cites] J Virol. 1997 Dec;71(12):9764-9 [9371642.001]
  • [Cites] J Virol. 1998 Jun;72(6):5182-8 [9573290.001]
  • [Cites] Annu Rev Cell Biol. 1988;4:487-525 [3058164.001]
  • [Cites] J Biol Chem. 1988 Dec 15;263(35):18726-31 [2461930.001]
  • [Cites] J Biol Chem. 1990 Feb 5;265(4):2168-72 [1688848.001]
  • [Cites] Cell. 1991 May 17;65(4):599-610 [2032285.001]
  • [Cites] J Invest Dermatol. 1992 May;98(5):764-70 [1569325.001]
  • [Cites] J Virol. 1999 Apr;73(4):3040-53 [10074154.001]
  • [Cites] Biochem Soc Symp. 1999;65:79-99 [10320934.001]
  • [Cites] J Biol Chem. 1999 Aug 20;274(34):24080-6 [10446179.001]
  • [Cites] J Nucl Med. 1999 Jun;40(6):1061-71 [10452325.001]
  • [Cites] J Virol. 2005 Jan;79(2):1191-206 [15613346.001]
  • [Cites] Exp Cell Res. 2005 Mar 10;304(1):317-27 [15707596.001]
  • [Cites] J Virol. 2005 Aug;79(16):10308-29 [16051824.001]
  • [Cites] J Virol. 2006 Feb;80(3):1167-80 [16414994.001]
  • [Cites] J Immunol. 2006 Feb 1;176(3):1741-9 [16424204.001]
  • [Cites] Science. 2006 Mar 31;311(5769):1921-4 [16574866.001]
  • [Cites] J Biol Chem. 2006 Jul 28;281(30):20932-9 [16731529.001]
  • [Cites] J Virol. 2006 Oct;80(20):10073-82 [17005685.001]
  • [Cites] Virology. 2006 Oct 10;354(1):103-15 [16879850.001]
  • [Cites] J Cell Biol. 1993 Jan;120(2):523-35 [8421064.001]
  • [Cites] J Biol Chem. 1993 Apr 25;268(12):8651-7 [8473308.001]
  • [Cites] Cell. 1993 Apr 23;73(2):309-19 [8477447.001]
  • [Cites] J Biol Chem. 1998 Jun 19;273(25):15854-9 [9624186.001]
  • [Cites] Biotechnology (N Y). 1995 Mar;13(3):265-70 [9634769.001]
  • [Cites] J Gen Virol. 1998 Jul;79 ( Pt 7):1573-91 [9680119.001]
  • [Cites] Biochemistry. 1998 Aug 4;37(31):10945-55 [9692987.001]
  • [Cites] J Cell Biol. 1998 Sep 7;142(5):1357-69 [9732295.001]
  • [Cites] N Engl J Med. 2000 Apr 6;342(14):1027-38 [10749966.001]
  • [Cites] J Biol Chem. 2000 Jul 21;275(29):21785-8 [10801897.001]
  • [Cites] J Cell Sci. 2000 Aug;113 ( Pt 16):2909-21 [10910775.001]
  • [Cites] Microsc Res Tech. 2000 Nov 1;51(3):280-301 [11054877.001]
  • [Cites] Virology. 2001 Apr 10;282(2):245-55 [11289807.001]
  • [Cites] Eur J Cancer. 2001 Jul;37(10):1251-69 [11423257.001]
  • [Cites] J Virol. 2001 Aug;75(16):7517-27 [11462024.001]
  • [Cites] Bioconjug Chem. 2002 Jan-Feb;13(1):128-35 [11792188.001]
  • [Cites] Chembiochem. 2000 Aug 18;1(2):107-14 [11828404.001]
  • [Cites] Cell. 2002 Feb 8;108(3):407-19 [11853674.001]
  • [Cites] Cell. 2002 Sep 20;110(6):673-87 [12297042.001]
  • [Cites] Cancer Res. 2002 Nov 1;62(21):6146-51 [12414640.001]
  • [Cites] BMC Biochem. 2001;2:10 [11696247.001]
  • [Cites] J Virol. 2003 Jan;77(2):1524-39 [12502866.001]
  • [Cites] J Virol. 2003 Mar;77(5):3131-47 [12584338.001]
  • [Cites] J Virol. 2003 Jun;77(11):6474-81 [12743304.001]
  • [Cites] J Biol Chem. 2003 Jun 13;278(24):21878-85 [12676956.001]
  • [Cites] J Virol. 2003 Oct;77(19):10179-85 [12970403.001]
  • [Cites] J Biochem. 2003 Oct;134(4):497-504 [14607975.001]
  • [Cites] J Virol. 2004 Apr;78(8):4207-23 [15047836.001]
  • [Cites] Biochim Biophys Acta. 2004 Jul 5;1692(2-3):103-19 [15246682.001]
  • [Cites] J Cell Biol. 1987 Oct;105(4):1873-84 [2822727.001]
  • [Cites] J Biol Chem. 1987 Dec 25;262(36):17294-8 [3693352.001]
  • [Cites] J Biol Chem. 1994 Jan 14;269(2):960-7 [7507113.001]
  • [Cites] Science. 1994 Apr 22;264(5158):569-71 [7512751.001]
  • [Cites] Mol Biol Cell. 1994 Feb;5(2):203-15 [8019006.001]
  • [Cites] J Biol Chem. 1994 Aug 12;269(32):20233-8 [8051114.001]
  • [Cites] J Pathol. 1994 May;173(1):23-31 [7523640.001]
  • [Cites] Infect Agents Dis. 1994 Feb;3(1):9-28 [7952927.001]
  • [Cites] Anal Biochem. 1994 Aug 1;220(2):360-6 [7978279.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] J Biochem. 1994 Oct;116(4):862-9 [7533763.001]
  • [Cites] Cell Immunol. 1995 Feb;160(2):165-72 [7536632.001]
  • [Cites] J Cell Sci. 1995 Jun;108 ( Pt 6):2511-23 [7673365.001]
  • [Cites] Nat Med. 1996 Mar;2(3):342-6 [8612236.001]
  • [Cites] Histopathology. 1996 Oct;29(4):337-46 [8910041.001]
  • [Cites] J Biol Chem. 1996 Nov 29;271(48):30587-94 [8940031.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14862-7 [8962146.001]
  • (PMID = 18045938.001).
  • [ISSN] 1098-5514
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / K02 AI049275; United States / NCI NIH HHS / CA / R01 CA091760; United States / NCI NIH HHS / CA / CA91760; United States / NIAID NIH HHS / AI / K02-AI49275
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Integrin alphaVbeta3; 0 / Receptors, Virus; 0 / Viral Envelope Proteins; 0 / glycoprotein B, human herpesvirus 8
  • [Other-IDs] NLM/ PMC2224453
  •  go-up   go-down


13. Kalt I, Borodianskiy-Shteinberg T, Schachor A, Sarid R: GLTSCR2/PICT-1, a putative tumor suppressor gene product, induces the nucleolar targeting of the Kaposi's sarcoma-associated herpesvirus KS-Bcl-2 protein. J Virol; 2010 Mar;84(6):2935-45
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] GLTSCR2/PICT-1, a putative tumor suppressor gene product, induces the nucleolar targeting of the Kaposi's sarcoma-associated herpesvirus KS-Bcl-2 protein.
  • KS-Bcl-2, encoded by Kaposi's sarcoma-associated herpesvirus (KSHV), is a structural and functional homologue of the Bcl-2 family of apoptosis regulators.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Virol. 2001 May;75(10):4843-53 [11312356.001]
  • [Cites] J Pathol. 2008 Oct;216(2):218-24 [18729076.001]
  • [Cites] J Virol. 2002 Mar;76(5):2551-6 [11836434.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3428-33 [11904405.001]
  • [Cites] Genes Dev. 2002 Oct 1;16(19):2465-78 [12368257.001]
  • [Cites] Mol Biol Cell. 2002 Nov;13(11):4100-9 [12429849.001]
  • [Cites] Microbiol Mol Biol Rev. 2003 Jun;67(2):175-212, table of contents [12794189.001]
  • [Cites] Trends Cell Biol. 2003 Sep;13(9):478-83 [12946627.001]
  • [Cites] Brain Res. 2004 Mar 19;1001(1-2):133-42 [14972662.001]
  • [Cites] J Biol Chem. 2004 Oct 29;279(44):45300-3 [15355975.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jan 21;94(2):690-4 [9012846.001]
  • [Cites] Nat Med. 1997 Mar;3(3):293-8 [9055856.001]
  • [Cites] J Biol Chem. 1997 May 23;272(21):13829-34 [9153240.001]
  • [Cites] J Virol. 1999 May;73(5):3810-7 [10196275.001]
  • [Cites] Genomics. 2000 Feb 15;64(1):44-50 [10708517.001]
  • [Cites] J Virol. 2000 Jun;74(11):5024-31 [10799576.001]
  • [Cites] Mol Cell. 2000 Jul;6(1):31-40 [10949025.001]
  • [Cites] Nat Cell Biol. 2000 Nov;2(11):819-25 [11056537.001]
  • [Cites] Genes Dev. 1999 Aug 1;13(15):1899-911 [10444588.001]
  • [Cites] Anal Biochem. 2005 Jan 1;336(1):138-40 [15582570.001]
  • [Cites] Nature. 2005 Jan 6;433(7021):77-83 [15635413.001]
  • [Cites] Biochem J. 2005 May 1;387(Pt 3):659-67 [15554878.001]
  • [Cites] Cell Cycle. 2005 Apr;4(4):590-6 [15876860.001]
  • [Cites] Crit Rev Clin Lab Sci. 2005;42(2):101-53 [15941082.001]
  • [Cites] Cell. 2005 Sep 23;122(6):927-39 [16179260.001]
  • [Cites] Arch Virol. 2005 Nov;150(11):2387-95 [15883654.001]
  • [Cites] Nat Cell Biol. 2006 Jul;8(7):688-99 [16799551.001]
  • [Cites] Cell Death Differ. 2006 Aug;13(8):1318-24 [16741528.001]
  • [Cites] Cell Death Differ. 2006 Aug;13(8):1339-50 [16763614.001]
  • [Cites] Mol Biol Cell. 2006 Nov;17(11):4888-95 [16971513.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 Jul;8(7):574-85 [17519961.001]
  • [Cites] Oncogene. 2007 Aug 30;26(40):5851-65 [17369848.001]
  • [Cites] Cell Death Differ. 2007 Nov;14(11):1872-9 [17657248.001]
  • [Cites] Virology. 2008 Feb 5;371(1):14-31 [17963810.001]
  • [Cites] Cell Death Differ. 2008 Mar;15(3):580-8 [18084238.001]
  • [Cites] Mol Cell. 2008 Jun 20;30(6):678-88 [18570871.001]
  • [Cites] Curr Biol. 2008 Jul 8;18(13):933-42 [18571408.001]
  • [Cites] FEBS J. 2008 Aug;275(16):4164-78 [18631361.001]
  • [Cites] J Virol. 2002 Mar;76(5):2469-79 [11836425.001]
  • (PMID = 20042497.001).
  • [ISSN] 1098-5514
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / GLTSCR2 protein, human; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Recombinant Fusion Proteins; 0 / Tumor Suppressor Proteins; 0 / Viral Proteins
  • [Other-IDs] NLM/ PMC2826064
  •  go-up   go-down


14. Ambinder RF, Bhatia K, Martinez-Maza O, Mitsuyasu R: Cancer biomarkers in HIV patients. Curr Opin HIV AIDS; 2010 Nov;5(6):531-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RECENT FINDINGS: CD4 lymphocyte count is associated with primary central nervous system lymphoma (PCNSL), systemic non-Hodgkin's lymphoma (NHL) (except perhaps for Burkitt lymphoma), Kaposi's sarcoma, cervical cancer, and anal cancer.
  • HIV load is associated with Burkitt lymphoma and systemic NHL (but not PCNSL), with Kaposi's sarcoma and with anal cancer.
  • EBV and Kaposi's sarcoma-associated herpesvirus (KSHV) have not yet emerged as especially promising markers of risk for either lymphoma or Kaposi's sarcoma.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AIDS. 2000 Jan 28;14(2):133-40 [10708283.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Nov;8(11):979-84 [10566552.001]
  • [Cites] Clin Immunol. 2003 Nov;109(2):119-29 [14597210.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2177-83 [15169806.001]
  • [Cites] Clin Infect Dis. 2004 Nov 1;39(9):1396-7; author reply 1397-8 [15494920.001]
  • [Cites] Blood. 1999 Mar 15;93(6):1838-42 [10068655.001]
  • [Cites] Cancer Res. 1999 Aug 1;59(15):3561-4 [10446961.001]
  • [Cites] Clin Immunol. 1999 Sep;92(3):293-9 [10479534.001]
  • [Cites] Gynecol Oncol. 2005 Mar;96(3):760-4 [15721423.001]
  • [Cites] Tumour Biol. 2006;27(4):187-94 [16651853.001]
  • [Cites] J Clin Virol. 2006 Aug;36(4):258-63 [16762591.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3786-91 [16917006.001]
  • [Cites] Int J Infect Dis. 2007 Mar;11(2):172-8 [16931088.001]
  • [Cites] Clin Infect Dis. 2007 Jul 1;45(1):103-10 [17554710.001]
  • [Cites] J Natl Cancer Inst. 2007 Jun 20;99(12):962-72 [17565153.001]
  • [Cites] PLoS Med. 2007 Mar 27;4(3):e96 [17388662.001]
  • [Cites] J Clin Virol. 2008 Aug;42(4):433-6 [18455472.001]
  • [Cites] J Clin Oncol. 2009 Feb 20;27(6):884-90 [19114688.001]
  • [Cites] J Acquir Immune Defic Syndr. 2009 Apr 1;50(4):427-9 [19322036.001]
  • [Cites] PLoS One. 2009;4(4):e5360 [19390683.001]
  • [Cites] J Clin Oncol. 2009 May 20;27(15):2496-502 [19349542.001]
  • [Cites] Haematologica. 2009 Jun;94(6):875-80 [19336735.001]
  • [Cites] J Infect Dis. 2009 Jul 1;200(1):79-87 [19476437.001]
  • [Cites] Blood. 2009 Jun 4;113(23):5737-42 [19336755.001]
  • [Cites] J Natl Cancer Inst. 2009 Aug 19;101(16):1120-30 [19648510.001]
  • [Cites] Blood. 2009 Sep 10;114(11):2354; author reply 2354-5 [19745076.001]
  • [Cites] Blood. 2009 Sep 24;114(13):2730-2 [19638620.001]
  • [Cites] J Acquir Immune Defic Syndr. 2009 Dec;52(5):611-22 [19770804.001]
  • [Cites] Lancet Oncol. 2009 Dec;10(12):1152-9 [19818686.001]
  • [Cites] Am J Epidemiol. 2010 Feb 1;171(3):267-76 [20047977.001]
  • [Cites] J Acquir Immune Defic Syndr. 2009 Oct 1;52(2):170-9 [19654554.001]
  • [Cites] Biol Blood Marrow Transplant. 2010 Feb;16(2):287-91 [19835968.001]
  • [Cites] J Clin Oncol. 2010 Feb 10;28(5):773-9 [20048176.001]
  • [Cites] Leuk Lymphoma. 2010 Mar;51(3):497-506 [20038229.001]
  • [Cites] J Clin Oncol. 2010 Mar 20;28(9):1514-9 [20177022.001]
  • [Cites] AIDS. 2010 Apr 24;24(7):1025-33 [20299965.001]
  • [Cites] Cancer Causes Control. 2010 May;21(5):759-69 [20087644.001]
  • [Cites] J Acquir Immune Defic Syndr. 2010 May 1;54(1):78-84 [20418723.001]
  • [Cites] Sex Transm Dis. 2010 May;37(5):311-5 [20065890.001]
  • [Cites] J Natl Cancer Inst. 2010 Jun 2;102(11):784-92 [20442214.001]
  • [Cites] BMC Cancer. 2010;10:278 [20537184.001]
  • [Cites] Clin Infect Dis. 2010 Aug 1;51(3):342-9 [20572760.001]
  • [Cites] PLoS One. 2010;5(7):e11448 [20625427.001]
  • [Cites] Blood. 2000 Oct 15;96(8):2730-4 [11023505.001]
  • (PMID = 20978397.001).
  • [ISSN] 1746-6318
  • [Journal-full-title] Current opinion in HIV and AIDS
  • [ISO-abbreviation] Curr Opin HIV AIDS
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA121947-05; United States / NCI NIH HHS / CA / CA096888-05S2; United States / NCI NIH HHS / CA / UO1 CA 121947; United States / NCI NIH HHS / CA / P50 CA096888-05S2; United States / NCI NIH HHS / CA / U01 CA121947; United States / NCI NIH HHS / CA / P50 CA096888
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ NIHMS274983; NLM/ PMC3055562
  •  go-up   go-down


15. Dresang LR, Vereide DT, Sugden B: Identifying sites bound by Epstein-Barr virus nuclear antigen 1 (EBNA1) in the human genome: defining a position-weighted matrix to predict sites bound by EBNA1 in viral genomes. J Virol; 2009 Apr;83(7):2930-40
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This PWM helped identify additional DNA-binding sites for EBNA1 in the genomes of EBV, Kaposi's sarcoma-associated herpesvirus, and cercopithecine herpesvirus 15 (CeHV-15) (also called herpesvirus papio 15).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 2000 Jun;118(6):1031-8 [10833477.001]
  • [Cites] Bioinformatics. 1998;14(1):48-54 [9520501.001]
  • [Cites] J Virol. 2001 Jul;75(13):5796-811 [11390581.001]
  • [Cites] J Virol. 2001 Nov;75(22):10603-11 [11602702.001]
  • [Cites] Intervirology. 2001;44(5):271-82 [11684888.001]
  • [Cites] J Virol. 2002 Jan;76(1):421-6 [11739708.001]
  • [Cites] Virology. 2003 Jul 5;311(2):263-74 [12842617.001]
  • [Cites] Mol Cell Biol. 2003 Oct;23(19):6901-8 [12972608.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14269-74 [14603034.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10(3):803-21 [14871955.001]
  • [Cites] Genome Res. 2004 Jun;14(6):1188-90 [15173120.001]
  • [Cites] Trends Mol Med. 2004 Jul;10(7):331-6 [15242681.001]
  • [Cites] Biomedicine. 1975 Jul;22(4):276-84 [179629.001]
  • [Cites] Int J Cancer. 1977 Oct 15;20(4):486-94 [199543.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Jul;77(7):4251-5 [6933474.001]
  • [Cites] Proc Natl Acad Sci U S A. 1984 Jun;81(12):3806-10 [6328526.001]
  • [Cites] Nature. 1984 Jul 19-25;310(5974):207-11 [6087149.001]
  • [Cites] Int J Cancer. 1985 Nov 15;36(5):545-7 [4055129.001]
  • [Cites] Mol Cell Biol. 1985 Oct;5(10):2533-42 [3016506.001]
  • [Cites] J Virol. 1986 Dec;60(3):1159-62 [3023667.001]
  • [Cites] Mol Cell Biol. 1986 Nov;6(11):3838-46 [3025615.001]
  • [Cites] Anal Biochem. 1987 Jul;164(1):44-52 [2823633.001]
  • [Cites] J Virol. 1989 Jun;63(6):2644-9 [2542577.001]
  • [Cites] J Virol. 1989 Jun;63(6):2657-66 [2542579.001]
  • [Cites] J Virol. 1990 May;64(5):2369-79 [2157891.001]
  • [Cites] J Virol. 1990 Jun;64(6):2876-83 [2159548.001]
  • [Cites] Nucleic Acids Res. 1990 Oct 25;18(20):6097-100 [2172928.001]
  • [Cites] J Biol Chem. 1991 Apr 25;266(12):7819-26 [1850421.001]
  • [Cites] J Virol. 1992 Jan;66(1):489-95 [1309258.001]
  • [Cites] J Virol. 1992 Aug;66(8):4654-61 [1321268.001]
  • [Cites] EMBO J. 1998 Nov 2;17(21):6394-403 [9799247.001]
  • [Cites] J Virol. 1999 Mar;73(3):1980-9 [9971778.001]
  • [Cites] Mol Cell Biol. 1999 May;19(5):3349-59 [10207059.001]
  • [Cites] J Clin Pathol. 1965 May;18:261-73 [14304234.001]
  • [Cites] Mol Cell Biol. 2006 Feb;26(3):1124-34 [16428463.001]
  • [Cites] Genome Res. 2006 Apr;16(4):466-76 [16533912.001]
  • [Cites] Nucleic Acids Res. 2006 Jul 1;34(Web Server issue):W369-73 [16845028.001]
  • [Cites] J Biol Chem. 2000 Jul 21;275(29):22273-7 [10801810.001]
  • [Cites] Oncogene. 2007 Jun 14;26(28):4135-47 [17486072.001]
  • [Cites] Blood. 2008 Jan 1;111(1):292-301 [17720884.001]
  • [Cites] J Virol. 2008 Feb;82(4):1679-87 [18077719.001]
  • [Cites] J Virol. 2008 Jun;82(12):5693-702 [18385243.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Jul 15;105(28):9639-44 [18621728.001]
  • [Cites] Cancer Res. 2008 Sep 1;68(17):6963-8 [18757410.001]
  • [Cites] Nature. 1992 Oct 8;359(6395):505-12 [1328886.001]
  • [Cites] J Virol. 1995 Apr;69(4):2633-6 [7884916.001]
  • [Cites] Cell. 1995 Oct 6;83(1):39-46 [7553871.001]
  • [Cites] Proc Int Conf Intell Syst Mol Biol. 1994;2:28-36 [7584402.001]
  • [Cites] Cell. 1996 Mar 8;84(5):791-800 [8625416.001]
  • [Cites] Intervirology. 1995;38(3-4):195-205 [8682617.001]
  • [Cites] J Virol. 1996 Sep;70(9):5758-68 [8709191.001]
  • [Cites] Virology. 1996 Aug 1;222(1):1-13 [8806482.001]
  • [Cites] Int J Cancer. 1997 Feb 7;70(4):375-82 [9033642.001]
  • [Cites] Nucleic Acids Res. 1997 Dec 15;25(24):4876-82 [9396791.001]
  • [Cites] J Virol. 1998 Jun;72(6):4657-66 [9573229.001]
  • [Cites] J Virol. 1998 Jul;72(7):6181-5 [9621086.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Sep 19;103(38):14188-93 [16966603.001]
  • (PMID = 19129441.001).
  • [ISSN] 1098-5514
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA022443; United States / NCI NIH HHS / CA / R01 CA133027
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / EBV-encoded nuclear antigen 1; 0 / Epstein-Barr Virus Nuclear Antigens; 9007-49-2 / DNA
  • [Other-IDs] NLM/ PMC2655553
  •  go-up   go-down


16. Nadal SR, Manzione CR, Horta SH: Comparison of perianal diseases in HIV-positive patients during periods before and after protease inhibitors use: what changed in the 21st century. Dis Colon Rectum; 2008 Oct;51(10):1491-4
MedlinePlus Health Information. consumer health - Rectal Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: In Group 1, the most common diseases were condylomas (24.7 percent), ulcers (21.8 percent), and anal fistulas (19.7 percent).
  • Tumors occurred in 2.5 percent, with Kaposi's sarcoma in 51.1 percent, and squamous-cell carcinoma in 27.6 percent.
  • The tumor incidence was 1.8 percent, with squamous-cell carcinoma in 59.4 percent and Kaposi's sarcoma in 23.2 percent.
  • Changes in incidence were statistically significant for the increase in condylomas and fissures, and for the decrease in ulcers, fistulas, and Kaposi's sarcoma among Group 2 patients.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18670819.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protease Inhibitors
  •  go-up   go-down


17. Guiguet M, Boué F, Cadranel J, Lang JM, Rosenthal E, Costagliola D, Clinical Epidemiology Group of the FHDH-ANRS CO4 cohort: Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncol; 2009 Dec;10(12):1152-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We investigated the incidence of both AIDS-defining cancers (Kaposi's sarcoma, non-Hodgkin lymphoma, and cervical cancer) and non-AIDS-defining cancers (Hodgkin's lymphoma, lung cancer, liver cancer, and anal cancer) in 52 278 patients followed up in the French Hospital Database on HIV cohort during 1998-2006 (median follow-up 4.9 years, IQR 2.1-7.9; 255 353 person-years).
  • FINDINGS: Current CD4 cell count was the most predictive risk factor for all malignancies apart from anal cancer.
  • Compared with patients with CD4 count greater than 500 cells per microL, rate ratios (RR) ranged from 1.9 (95% CI 1.3-2.7) for CD4 counts 350-499 cells per microL to 25.2 (17.1-37.0) for counts less than 50 cells per microL for Kaposi's sarcoma (p<0.0001), from 1.3 (0.9-2.0) to 14.8 (9.7-22.6) for non-Hodgkin lymphoma (p<0.0001), from 1.2 (0.7-2.2) to 5.4 (2.4-12.1) for Hodgkin's lymphoma (p<0.0001), from 2.2 (1.3-3.6) to 8.5 (4.3-16.7) for lung cancer (p<0.0001), and from 2.0 (0.9-4.5) to 7.6 (2.7-20.8) for liver cancer (p<0.0001).
  • The risk of Kaposi's sarcoma and non-Hodgkin lymphoma increased for current plasma HIV RNA greater than 100 000 copies per mL compared with patients with controlled viral load (RR 3.1, 95% CI 2.3-4.2, p<0.0001; and 2.9, 2.1-3.9, p<0.0001, respectively), whereas cART was independently associated with a decreased incidence (0.3, 0.2-0.4, p<0.0001; and 0.8, 0.6-1.0, p=0.07, respectively).
  • The risk of anal cancer increased with the time during which the CD4 count was less than 200 cells per microL (1.3 per year, 1.2-1.5; p=0.0001), and viral load was greater than 100 000 copies per mL (1.2 per year, 1.1-1.4, p=0.005).


18. Dhir AA, Sawant SP: Malignancies in HIV: the Indian scenario. Curr Opin Oncol; 2008 Sep;20(5):517-21
MedlinePlus Health Information. consumer health - HIV/AIDS.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Kaposi's sarcoma is rare in India.
  • Amongst the non-AIDS defining cancers anal cancer, testicular cancer, Hodgkin's disease, colon cancer and certain head and neck cancer sites in men and vaginal cancers among women were found to occur more frequently.

  • Genetic Alliance. consumer health - HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19106653.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 37
  •  go-up   go-down


19. Barbaro G, Barbarini G: HIV infection and cancer in the era of highly active antiretroviral therapy (Review). Oncol Rep; 2007 May;17(5):1121-6
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The majority of cancers affecting HIV-infected subjects are those established as acquired immunodeficiency syndrome (AIDS)-defining: Kaposi's sarcoma (KS), non-Hodgkin's lymphoma (NHL), and invasive cervical cancer (ICC).
  • However, other types of cancer, such as Hodgkin's disease (HD), anal cancer, lung cancer and testicular germ cell tumors appear to be more common among HIV-infected subjects compared to the general population.
  • While a significant decrease in the incidence of KS has been observed, HAART has not had a significant impact on NHL incidence, particularly systemic NHL, or on ICC, HD, anal cancers and other non-AIDS-defining cancers.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17390054.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Greece
  • [Number-of-references] 44
  •  go-up   go-down


20. Dhir AA, Sawant S, Dikshit RP, Parikh P, Srivastava S, Badwe R, Rajadhyaksha S, Dinshaw KA: Spectrum of HIV/AIDS related cancers in India. Cancer Causes Control; 2008 Mar;19(2):147-53
MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: No case of Kaposi's sarcoma was observed.
  • In males, PIR was increased for anal cancer (PIR = 10.3, 95%CI 4.30-24.83), Hodgkin's disease, testicular cancer, colon cancer, and few head and neck cancer sites.
  • Among females, the PIRs for cervical cancer (PIR = 4.1, 95%CI 2.90-5.75), vaginal cancer (PIR = 7.7, 95%CI 2.48-23.85), and anal cancer (PIR = 6.5, 95%CI 0.91-45.88) were increased.
  • CONCLUSIONS: The absence of Kaposi's sarcoma and increased PIRs for certain non-AIDS defining cancers among HIV infected cancer cases indicates a different spectrum of HIV associated malignancies in this region.


21. Spano JP, Costagliola D, Katlama C, Mounier N, Oksenhendler E, Khayat D: AIDS-related malignancies: state of the art and therapeutic challenges. J Clin Oncol; 2008 Oct 10;26(29):4834-42
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although the advent of cART has resulted in reductions in the incidence of Kaposi's sarcoma and non-Hodgkin's lymphoma, non-AIDS-defining malignancies present an increased risk for HIV-infected patients, characterized by some common clinical features, generally with a more aggressive behavior and a more advanced disease at diagnosis, which is responsible for poorer patient outcomes.
  • Specific therapeutic recommendations are lacking for these new nonopportunistic malignancies, such as Hodgkin's lymphoma, anal cancer, lung cancer, hepatocarcinoma, and many others.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18591544.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 99
  •  go-up   go-down


22. Mathew SS, Bryant PW, Burch AD: Accumulation of oxidized proteins in Herpesvirus infected cells. Free Radic Biol Med; 2010 Aug 1;49(3):383-91
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here we show that oxidized proteins accumulate during infections with two distantly related herpesviruses, HSV-1 and Rhesus Rhadinovirus (RRV), a close relative of the Kaposi's sarcoma-associated herpesvirus (KSHV).

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • [Cites] Free Radic Biol Med. 1999 Dec;27(11-12):1151-63 [10641706.001]
  • [Cites] Exp Eye Res. 2000 Feb;70(2):215-20 [10655147.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 May 23;97(11):5746-9 [10811907.001]
  • [Cites] Methods Mol Biol. 2000;99:15-24 [10909073.001]
  • [Cites] Drug Metab Rev. 2000 Aug-Nov;32(3-4):307-26 [11139131.001]
  • [Cites] Biochimie. 2001 Mar-Apr;83(3-4):301-10 [11295490.001]
  • [Cites] Free Radic Biol Med. 2001 May 15;30(10):1171-6 [11369508.001]
  • [Cites] EMBO J. 2001 Sep 17;20(18):5280-9 [11566891.001]
  • [Cites] IUBMB Life. 2001 Dec;52(6):303-7 [11895079.001]
  • [Cites] Free Radic Biol Med. 2002 May 1;32(9):790-6 [11978480.001]
  • [Cites] Biochem Pharmacol. 2002 Sep;64(5-6):1019-26 [12213601.001]
  • [Cites] Ann N Y Acad Sci. 2002 Nov;973:488-504 [12485918.001]
  • [Cites] Trends Mol Med. 2003 Apr;9(4):169-76 [12727143.001]
  • [Cites] Virology. 2003 Jul 20;312(1):122-34 [12890626.001]
  • [Cites] Circulation. 2004 Feb 3;109(4):500-5 [14732750.001]
  • [Cites] J Virol. 2004 Jul;78(13):7175-85 [15194794.001]
  • [Cites] Int J Biochem Cell Biol. 2004 Dec;36(12):2519-30 [15325589.001]
  • [Cites] J Virol. 1978 Sep;27(3):490-504 [212578.001]
  • [Cites] Free Radic Res Commun. 1986;1(6):361-7 [3505892.001]
  • [Cites] Methods Enzymol. 1990;186:464-78 [1978225.001]
  • [Cites] Methods Enzymol. 1994;233:346-57 [8015469.001]
  • [Cites] J Biol Chem. 1995 Feb 3;270(5):2344-51 [7836468.001]
  • [Cites] Ann Med. 1994 Dec;26(6):435-41 [7695870.001]
  • [Cites] J Neurochem. 1995 Nov;65(5):2146-56 [7595501.001]
  • [Cites] Antiviral Res. 1995 Jun;27(3):237-53 [8540746.001]
  • [Cites] J Biol Chem. 1996 Jun 28;271(26):15504-9 [8663134.001]
  • [Cites] Free Radic Biol Med. 1996;21(5):641-9 [8891667.001]
  • [Cites] FASEB J. 1997 Jun;11(7):526-34 [9212076.001]
  • [Cites] J Proteome Res. 2008 Sep;7(9):3868-78 [18652502.001]
  • [Cites] J Virol. 2009 Sep;83(18):9304-12 [19587060.001]
  • [Cites] PLoS Pathog. 2009 Oct;5(10):e1000619 [19816571.001]
  • [Cites] J Biol Chem. 1997 Aug 15;272(33):20313-6 [9252331.001]
  • [Cites] Anal Biochem. 1999 Jan 1;266(1):48-57 [9887212.001]
  • [Cites] Arch Biochem Biophys. 1999 Feb 15;362(2):211-6 [9989929.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 May 25;96(11):6223-8 [10339569.001]
  • [Cites] Free Radic Biol Med. 2004 Dec 15;37(12):2072-81 [15544925.001]
  • [Cites] Antioxid Redox Signal. 2005 Mar-Apr;7(3-4):414-22 [15706088.001]
  • [Cites] J Biol Chem. 2005 Mar 25;280(12):11648-55 [15659387.001]
  • [Cites] EMBO J. 2005 Apr 6;24(7):1311-7 [15775985.001]
  • [Cites] J Virol. 2005 Aug;79(16):10740-9 [16051866.001]
  • [Cites] Free Radic Biol Med. 2005 Nov 1;39(9):1208-15 [16214036.001]
  • [Cites] Proteomics. 2006 Feb;6(4):1250-60 [16408314.001]
  • [Cites] J Virol. 2006 Apr;80(7):3567-81 [16537625.001]
  • [Cites] J Cell Mol Med. 2006 Apr-Jun;10(2):389-406 [16796807.001]
  • [Cites] Exp Cell Res. 2007 Jan 1;313(1):195-209 [17123510.001]
  • [Cites] J Neurovirol. 2007 Oct;13(5):416-25 [17994426.001]
  • [Cites] PLoS One. 2008;3(1):e1491 [18231578.001]
  • [Cites] J Virol. 2008 Apr;82(7):3381-90 [18234803.001]
  • [Cites] Mol Cell Biochem. 2008 Jun;313(1-2):179-86 [18414998.001]
  • [Cites] J Virol. 2008 Jul;82(13):6324-36 [18434395.001]
  • (PMID = 20441790.001).
  • [ISSN] 1873-4596
  • [Journal-full-title] Free radical biology & medicine
  • [ISO-abbreviation] Free Radic. Biol. Med.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / K22 AI062991; United States / NIAID NIH HHS / AI / K22AI062991
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HSP27 Heat-Shock Proteins; 0 / Molecular Chaperones; 0 / Proteins; EC 3.4.25.1 / Proteasome Endopeptidase Complex
  • [Other-IDs] NLM/ NIHMS233650; NLM/ PMC3206308
  •  go-up   go-down


23. Butler LM, Neilands TB, Mosam A, Mzolo S, Martin JN: A population-based study of how children are exposed to saliva in KwaZulu-Natal Province, South Africa: implications for the spread of saliva-borne pathogens to children. Trop Med Int Health; 2010 Apr;15(4):442-53
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: In sub-Saharan Africa, many viral infections, including Epstein-Barr virus, cytomegalovirus, Kaposi's sarcoma-associated herpesvirus and hepatitis B are acquired in childhood.
  • RESULTS: We identified 12 caregiving practices that expose a child's oral-respiratory mucosa, cutaneous surfaces or anal-rectal mucosa to saliva.

  • MedlinePlus Health Information. consumer health - Child Care.
  • MedlinePlus Health Information. consumer health - Viral Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2000 Jan 1;85(1):54-9 [10585583.001]
  • [Cites] Pediatrics. 2009 Aug;124(2):658-66 [19620190.001]
  • [Cites] J Med Virol. 2000 Aug;61(4):433-8 [10897060.001]
  • [Cites] Lancet. 2000 Sep 23;356(9235):1062-5 [11009141.001]
  • [Cites] Parassitologia. 2002 Jun;44(1-2):123-9 [12404820.001]
  • [Cites] J Infect Dis. 2003 Jun 1;187(11):1780-5 [12751036.001]
  • [Cites] Br J Cancer. 2003 Nov 17;89(10):2016-7 [14612917.001]
  • [Cites] J Infect Dis. 2004 Sep 15;190(6):1068-75 [15319855.001]
  • [Cites] Nature. 1978 Aug 24;274(5673):756-61 [210392.001]
  • [Cites] Int J Cancer. 1978 Sep 15;22(3):239-43 [212369.001]
  • [Cites] Lancet. 1981 Nov 21;2(8256):1129-33 [6118576.001]
  • [Cites] Bull World Health Organ. 1981;59(4):605-10 [6274535.001]
  • [Cites] Lancet. 1983 May 28;1(8335):1203-6 [6133999.001]
  • [Cites] J Clin Pathol. 1991 May;44(5):366-9 [1646236.001]
  • [Cites] Epidemiol Rev. 1991;13:42-59 [1765119.001]
  • [Cites] J Pediatr. 1992 Apr;120(4 Pt 1):563-4 [1552394.001]
  • [Cites] New Microbiol. 1993 Jan;16(1):83-5 [8385733.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] Am J Epidemiol. 1998 Mar 1;147(5):478-87 [9525535.001]
  • [Cites] Int J Cancer. 1998 Sep 11;77(6):817-20 [9714046.001]
  • [Cites] Int J Cancer. 1999 Apr 12;81(2):189-92 [10188717.001]
  • [Cites] Lancet Infect Dis. 2004 Dec;4(12):725-38 [15567122.001]
  • [Cites] J Infect Dis. 2006 Feb 1;193(3):422-6 [16388490.001]
  • [Cites] Trop Med Int Health. 2007 Jan;12(1):150-5 [17207159.001]
  • [Cites] PLoS Med. 2007 Dec;4(12):e334 [18052600.001]
  • [Cites] J Acquir Immune Defic Syndr. 2009 Feb 1;50(2):162-7 [19131893.001]
  • [Cites] J Infect Dis. 2009 Aug 1;200(3):430-8 [19534596.001]
  • [Cites] Int J STD AIDS. 2009 Aug;20(8):553-6 [19625587.001]
  • [Cites] Br J Cancer. 2000 May;82(9):1585-92 [10789729.001]
  • (PMID = 20149165.001).
  • [ISSN] 1365-3156
  • [Journal-full-title] Tropical medicine & international health : TM & IH
  • [ISO-abbreviation] Trop. Med. Int. Health
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / K01 HD052020
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS582774; NLM/ PMC4104610
  •  go-up   go-down


24. Bonnet F, Chêne G: Evolving epidemiology of malignancies in HIV. Curr Opin Oncol; 2008 Sep;20(5):534-40
MedlinePlus Health Information. consumer health - HIV/AIDS.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Since the introduction of combination antiretroviral therapy, the incidence of Kaposi's sarcoma and cerebral lymphoma (among AIDS-defining cancers) decreased in parallel with AIDS-defining infections, whereas the incidence of systemic non-Hodgkin's lymphoma and cervical cancer decreased less than others and remains higher in HIV-infected patients than in the general population.
  • These malignancies include Hodgkin's disease, lung, anal, head and neck cancers, hemopathies, and conjunctival cancers.

  • Genetic Alliance. consumer health - HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19106656.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 75
  •  go-up   go-down


25. Morton LM, Curtis RE, Linet MS, Bluhm EC, Tucker MA, Caporaso N, Ries LA, Fraumeni JF Jr: Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype. J Clin Oncol; 2010 Nov 20;28(33):4935-44
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients with HIV/AIDS-related lymphoma (n = 932) were predominantly diagnosed with DLBCL and had significantly and substantially elevated risks for second anal cancer (SIR = 120.50) and Kaposi's sarcoma (SIR = 138.90).

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):925-33 [15824165.001]
  • [Cites] Am J Epidemiol. 2010 Feb 1;171(3):267-76 [20047977.001]
  • [Cites] Br J Cancer. 2005 Jul 11;93(1):159-66 [15970927.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Oct;14(10):2402-6 [16214923.001]
  • [Cites] N Engl J Med. 2005 Nov 17;353(20):2135-47 [16291983.001]
  • [Cites] Lung Cancer. 2005 Dec;50(3):419-20 [16125820.001]
  • [Cites] J Clin Oncol. 2006 Apr 1;24(10):1568-74 [16520465.001]
  • [Cites] Cancer. 2006 Jul 1;107(1):108-15 [16708354.001]
  • [Cites] Haematologica. 2006 Nov;91(11):1481-8 [17043014.001]
  • [Cites] Leuk Lymphoma. 2006 Nov;47(11):2314-20 [17107903.001]
  • [Cites] AIDS. 2007 Jan 11;21(2):207-13 [17197812.001]
  • [Cites] Int J Cancer. 2007 Mar 1;120(5):1099-102 [17131330.001]
  • [Cites] Cancer Causes Control. 2007 Mar;18(2):135-42 [17235495.001]
  • [Cites] Int J Cancer. 2007 Jul 1;121(1):151-6 [17351903.001]
  • [Cites] Blood. 2007 Jun 1;109(11):4617-26 [17311989.001]
  • [Cites] Blood. 2007 Jul 15;110(2):695-708 [17389762.001]
  • [Cites] Lancet. 2007 Jul 7;370(9581):59-67 [17617273.001]
  • [Cites] Int J Cancer. 2008 Jan 1;122(1):144-54 [17708556.001]
  • [Cites] Cancer Causes Control. 2008 Feb;19(1):43-50 [17906957.001]
  • [Cites] Haematologica. 2008 Mar;93(3):398-404 [18268277.001]
  • [Cites] Clin Gastroenterol Hepatol. 2008 Apr;6(4):451-8 [18387498.001]
  • [Cites] Blood. 2008 Apr 15;111(8):4029-38 [18263783.001]
  • [Cites] J Clin Oncol. 2008 Apr 10;26(11):1850-7 [18347006.001]
  • [Cites] Expert Rev Anticancer Ther. 2008 Apr;8(4):605-15 [18402527.001]
  • [Cites] Int J Cancer. 2008 Jul 1;123(1):187-94 [18435450.001]
  • [Cites] Expert Opin Pharmacother. 2008 Jun;9(9):1481-94 [18518779.001]
  • [Cites] Hematol Oncol Clin North Am. 2008 Oct;22(5):941-52, ix [18954744.001]
  • [Cites] Blood. 2008 Dec 15;112(13):5150-60 [18796628.001]
  • [Cites] Blood. 2009 Jan 29;113(5):1175-83 [18971419.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2454-60 [10561309.001]
  • [Cites] Cancer. 2001 Feb 15;91(4):874-80 [11241258.001]
  • [Cites] J Clin Oncol. 2001 Mar 15;19(6):1610-8 [11250989.001]
  • [Cites] J Natl Cancer Inst. 2002 Feb 6;94(3):182-92 [11830608.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1 Suppl 2):10-24 [11842384.001]
  • [Cites] J Clin Oncol. 2002 Sep 15;20(18):3878-84 [12228208.001]
  • [Cites] Br J Cancer. 2003 Jan 13;88(1):74-8 [12556962.001]
  • [Cites] Med Oncol. 2003;20(3):211-20 [14514970.001]
  • [Cites] Eur J Cancer. 2004 Feb;40(3):383-9 [14746857.001]
  • [Cites] Blood. 2004 Feb 15;103(4):1222-8 [14576060.001]
  • [Cites] Cancer. 2004 May 1;100(9):1902-8 [15112271.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Aug 15;36(5):1083-91 [15247562.001]
  • [Cites] J Natl Cancer Inst. 1992 Sep 16;84(18):1422-7 [1512794.001]
  • [Cites] Eur J Haematol. 1994 Oct;53(4):218-22 [7957806.001]
  • [Cites] J Natl Cancer Inst. 1995 Apr 5;87(7):524-30 [7707439.001]
  • [Cites] J Clin Oncol. 1996 Feb;14(2):565-71 [8636772.001]
  • [Cites] Int J Cancer. 1997 Nov 27;73(5):645-50 [9398040.001]
  • [Cites] Cancer. 2005 Jan 15;103(2):216-28 [15578683.001]
  • [Cites] N Engl J Med. 2009 Feb 12;360(7):659-67 [19213679.001]
  • [Cites] J Natl Cancer Inst. 2009 Feb 18;101(4):248-55 [19211444.001]
  • [Cites] J Clin Oncol. 2009 Feb 20;27(6):904-10 [19114699.001]
  • [Cites] Nat Genet. 2009 Aug;41(8):873-5 [19620980.001]
  • [Cites] J Natl Cancer Inst. 2009 Aug 19;101(16):1120-30 [19648510.001]
  • [Cites] Blood. 2005 Jun 15;105(12):4573-5 [15741224.001]
  • (PMID = 20940199.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3020697
  •  go-up   go-down


26. O'Connor CM, Kedes DH: Mass spectrometric analyses of purified rhesus monkey rhadinovirus reveal 33 virion-associated proteins. J Virol; 2006 Feb;80(3):1574-83
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The repertoire of proteins that comprise intact gammaherpesviruses, including the human pathogen Kaposi's sarcoma-associated herpesvirus (KSHV), is likely to have critical functions not only in viral structure and assembly but also in the early stages of infection and evasion of the host's rapidly deployed antiviral defenses.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Virol. 2001 Mar;75(6):2866-78 [11222712.001]
  • [Cites] J Virol. 2001 Mar;75(6):2879-90 [11222713.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] Virology. 1995 Jan 10;206(1):465-78 [7831802.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]
  • [Cites] J Virol. 1996 Feb;70(2):1242-5 [8551588.001]
  • [Cites] Nat Med. 1996 Mar;2(3):342-6 [8612236.001]
  • [Cites] J Virol. 1996 Aug;70(8):5455-65 [8764057.001]
  • [Cites] J Virol. 1996 Nov;70(11):8047-54 [8892929.001]
  • [Cites] J Cell Biol. 1997 Mar 10;136(5):1007-21 [9060466.001]
  • [Cites] AIDS. 1997 Apr;11(5):F35-45 [9108935.001]
  • [Cites] J Virol. 1997 Dec;71(12):9764-9 [9371642.001]
  • [Cites] Virology. 1998 Mar 30;243(1):208-17 [9527930.001]
  • [Cites] Virology. 1998 Sep 15;249(1):140-9 [9740785.001]
  • [Cites] J Virol Methods. 1998 Aug;73(2):219-28 [9766893.001]
  • [Cites] Virology. 1998 Nov 25;251(2):402-13 [9837804.001]
  • [Cites] J Virol. 1999 Feb;73(2):1341-9 [9882339.001]
  • [Cites] Nat Biotechnol. 2001 Mar;19(3):242-7 [11231557.001]
  • [Cites] Virology. 2001 Jun 5;284(2):235-49 [11384223.001]
  • [Cites] J Virol. 2004 Oct;78(20):10960-6 [15452216.001]
  • [Cites] J Virol. 2004 Nov;78(22):12668-71 [15507654.001]
  • [Cites] J Virol. 1976 Mar;17(3):935-49 [176452.001]
  • [Cites] J Virol. 1976 Apr;18(1):289-97 [176465.001]
  • [Cites] Annu Rev Biochem. 1981;50:555-83 [7023366.001]
  • [Cites] J Gen Virol. 1982 Jan;58 Pt 1:149-61 [6292340.001]
  • [Cites] J Gen Virol. 1983 Jan;64 (Pt 1):19-35 [6296297.001]
  • [Cites] J Virol. 1983 Sep;47(3):463-70 [6312078.001]
  • [Cites] J Virol. 1983 Nov;48(2):521-33 [6312106.001]
  • [Cites] J Virol. 1984 Dec;52(3):872-83 [6092717.001]
  • [Cites] Biol Cell. 1984;51(2):115-31 [6097326.001]
  • [Cites] J Virol. 1985 Oct;56(1):127-34 [2993643.001]
  • [Cites] J Virol. 1986 May;58(2):339-47 [3009851.001]
  • [Cites] J Virol. 1986 Aug;59(2):216-23 [3016293.001]
  • [Cites] J Virol. 1988 Aug;62(8):2850-8 [2455821.001]
  • [Cites] Annu Rev Microbiol. 1988;42:489-516 [3144239.001]
  • [Cites] APMIS Suppl. 1992;27:84-95 [1325817.001]
  • [Cites] J Virol. 1992 Nov;66(11):6706-13 [1328686.001]
  • [Cites] J Virol. 1999 Apr;73(4):3040-53 [10074154.001]
  • [Cites] J Gen Virol. 1999 May;80 ( Pt 5):1305-10 [10355777.001]
  • [Cites] Nat Biotechnol. 1999 Jul;17(7):676-82 [10404161.001]
  • [Cites] Virology. 1999 Sep 15;262(1):237-49 [10489357.001]
  • [Cites] Biol Reprod. 1999 Nov;61(5):1184-97 [10529264.001]
  • [Cites] J Biol Chem. 1957 May;226(1):497-509 [13428781.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Nov 16;101(46):16286-91 [15534216.001]
  • [Cites] J Virol. 2005 Jan;79(2):800-11 [15613308.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3805-10 [15738413.001]
  • [Cites] J Virol. 2005 Apr;79(8):4952-64 [15795281.001]
  • [Cites] J Biol Chem. 2004 Sep 10;279(37):38325-30 [15247271.001]
  • [Cites] J Virol. 2000 Apr;74(7):3388-98 [10708456.001]
  • [Cites] Methods Mol Biol. 2000;146:17-26 [10948494.001]
  • [Cites] J Virol. 2000 Oct;74(20):9646-54 [11000237.001]
  • [Cites] J Virol. 2001 Feb;75(3):1427-36 [11152516.001]
  • [Cites] J Virol. 2001 Nov;75(22):10923-32 [11602732.001]
  • [Cites] Genes Cells. 2001 Nov;6(11):955-66 [11733033.001]
  • [Cites] Anal Chem. 2001 Dec 1;73(23):5683-90 [11774908.001]
  • [Cites] J Virol. 2002 Feb;76(4):1537-47 [11799148.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Apr 16;99(8):5573-8 [11943871.001]
  • [Cites] Virus Genes. 2002 Jun;24(3):257-66 [12086147.001]
  • [Cites] J Virol. 2003 Jan;77(1):592-9 [12477863.001]
  • [Cites] J Virol. 2003 Apr;77(7):4221-30 [12634379.001]
  • [Cites] J Virol. 2003 Apr;77(7):4291-7 [12634386.001]
  • [Cites] J Biol Chem. 2003 Mar 14;278(11):9283-9 [12645526.001]
  • [Cites] J Virol. 2003 Dec;77(24):13182-93 [14645575.001]
  • [Cites] J Virol. 2003 Dec;77(24):13425-32 [14645600.001]
  • [Cites] J Virol. 2003 Dec;77(24):13439-47 [14645602.001]
  • [Cites] Glycobiology. 2000 Dec;10(12):1259-69 [11159917.001]
  • (PMID = 16415032.001).
  • [ISSN] 0022-538X
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA088768; United States / NCI NIH HHS / CA / R01 CA 88768
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Capsid Proteins; 0 / Detergents; 0 / Viral Proteins; EC 3.4.- / Peptide Hydrolases
  • [Other-IDs] NLM/ PMC1346966
  •  go-up   go-down


27. Kovaleva M, Bussmeyer I, Rabe B, Grötzinger J, Sudarman E, Eichler J, Conrad U, Rose-John S, Scheller J: Abrogation of viral interleukin-6 (vIL-6)-induced signaling by intracellular retention and neutralization of vIL-6 with an anti-vIL-6 single-chain antibody selected by phage display. J Virol; 2006 Sep;80(17):8510-20
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Viral interleukin (vIL-6) is believed to play an important role in the pathogenesis of Kaposi's sarcoma as well as primary effusion lymphoma and multicentric Castleman's disease.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1994 Feb 1;91(3):1119-23 [8302840.001]
  • [Cites] Science. 1994 Jun 3;264(5164):1415-21 [8197455.001]
  • [Cites] Biochem J. 1994 Jun 1;300 ( Pt 2):281-90 [8002928.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] N Engl J Med. 1995 May 4;332(18):1186-91 [7700311.001]
  • [Cites] Blood. 1995 Aug 15;86(4):1276-80 [7632932.001]
  • [Cites] J Exp Med. 1996 Apr 1;183(4):1399-406 [8666898.001]
  • [Cites] Blood. 1996 Jul 15;88(2):645-56 [8695812.001]
  • [Cites] Science. 1996 Dec 6;274(5293):1739-44 [8939871.001]
  • [Cites] J Virol. 1997 Jan;71(1):839-42 [8985427.001]
  • [Cites] J Exp Med. 1997 Feb 17;185(4):755-66 [9034153.001]
  • [Cites] Nat Biotechnol. 1997 Feb;15(2):142-5 [9035138.001]
  • [Cites] Proteins. 1997 Jan;27(1):96-109 [9037715.001]
  • [Cites] Comb Chem High Throughput Screen. 2005 Mar;8(2):117-26 [15777175.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3797-802 [16091453.001]
  • [Cites] Science. 2001 Mar 16;291(5511):2150-5 [11251120.001]
  • [Cites] Immunity. 2001 Jun;14(6):705-14 [11420041.001]
  • [Cites] Blood. 2001 Nov 15;98(10):3042-9 [11698289.001]
  • [Cites] Blood. 1998 Mar 15;91(6):1858-63 [9490667.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):3251-6 [9501249.001]
  • [Cites] J Biol Chem. 1998 Oct 16;273(42):27213-9 [9765242.001]
  • [Cites] Blood. 1998 Nov 15;92(10):3495-504 [9808540.001]
  • [Cites] Blood. 1999 Mar 1;93(5):1487-95 [10029575.001]
  • [Cites] J Virol. 1999 May;73(5):4181-7 [10196314.001]
  • [Cites] Glia. 1999 May;26(3):191-200 [10340760.001]
  • [Cites] Blood. 1999 Jun 15;93(12):4034-43 [10361100.001]
  • [Cites] J Mol Biol. 2002 Jan 25;315(4):637-46 [11812136.001]
  • [Cites] Blood. 2002 Apr 1;99(7):2331-6 [11895764.001]
  • [Cites] AIDS. 2002 May 24;16(8):F9-18 [12004288.001]
  • [Cites] Science. 2002 Nov 15;298(5597):1432-5 [12434062.001]
  • [Cites] Biochemistry. 2003 May 13;42(18):5244-52 [12731865.001]
  • [Cites] J Immunol. 2003 Sep 15;171(6):3202-9 [12960349.001]
  • [Cites] Plant J. 1999 Dec;20(5):601-10 [10652132.001]
  • [Cites] J Immunol. 2000 May 1;164(9):4672-7 [10779772.001]
  • [Cites] Nat Med. 2000 May;6(5):583-8 [10802717.001]
  • [Cites] Leuk Lymphoma. 2000 Jul;38(3-4):387-94 [10830746.001]
  • [Cites] Eur J Biochem. 2000 Jun;267(12):3604-12 [10848977.001]
  • [Cites] J Exp Med. 1997 Mar 17;185(6):1005-12 [9091574.001]
  • [Cites] Immunity. 1997 Mar;6(3):315-25 [9075932.001]
  • [Cites] Annu Rev Immunol. 1997;15:797-819 [9143707.001]
  • [Cites] Science. 1997 Jun 20;276(5320):1851-4 [9188529.001]
  • [Cites] J Biol Chem. 1997 Aug 1;272(31):19625-31 [9235971.001]
  • [Cites] FEBS Lett. 1997 Sep 15;414(3):557-61 [9323035.001]
  • [Cites] Am J Pathol. 1997 Dec;151(6):1517-22 [9403701.001]
  • [Cites] Science. 1997 Dec 12;278(5345):1969-70; author reply 1972-3 [9417642.001]
  • [Cites] Blood. 1999 Aug 1;94(3):923-31 [10419883.001]
  • [Cites] J Virol. 1999 Oct;73(10):8268-78 [10482577.001]
  • [Cites] Biol Chem. 1999 Jul-Aug;380(7-8):803-13 [10494829.001]
  • [Cites] J Immunol. 1999 Oct 15;163(8):4583-9 [10510402.001]
  • [Cites] Blood. 1999 Oct 15;94(8):2871-9 [10515891.001]
  • [Cites] Blood. 1999 Oct 15;94(8):2931-3 [10515899.001]
  • [Cites] J Biol Chem. 2004 Dec 10;279(50):51793-803 [15258150.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Jan 28;326(4):724-8 [15607729.001]
  • [Cites] Mol Pathol. 2000 Apr;53(2):69-76 [10889905.001]
  • [Cites] J Virol. 2000 Nov;74(21):10187-93 [11024147.001]
  • [Cites] Eur J Biochem. 2001 Jan;268(1):160-7 [11121117.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2506-12 [12791661.001]
  • [Cites] J Immunol. 2004 Feb 15;172(4):2225-31 [14764690.001]
  • [Cites] J Exp Med. 2004 Feb 16;199(4):503-14 [14970177.001]
  • [Cites] J Immunol Methods. 2004 Aug;291(1-2):93-100 [15345308.001]
  • [Cites] Immunity. 2004 Oct;21(4):491-501 [15485627.001]
  • [Cites] Nature. 1970 Aug 15;227(5259):680-5 [5432063.001]
  • [Cites] Science. 1985 Jun 14;228(4705):1315-7 [4001944.001]
  • [Cites] Cell. 1985 Jul;41(3):727-34 [3924409.001]
  • [Cites] Gene. 1989 Apr 15;77(1):51-9 [2744487.001]
  • [Cites] Gene. 1989 Apr 15;77(1):61-8 [2744488.001]
  • [Cites] J Exp Med. 1989 Oct 1;170(4):1409-14 [2529343.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Sep;87(18):6934-8 [2169613.001]
  • [Cites] Nature. 1990 Dec 6;348(6301):552-4 [2247164.001]
  • [Cites] Trends Biochem Sci. 1990 Dec;15(12):483-6 [2077689.001]
  • [Cites] Proteins. 1990;8(4):309-14 [1708882.001]
  • [Cites] EMBO J. 1991 Oct;10(10):2821-32 [1833184.001]
  • [Cites] J Immunol. 1992 Apr 1;148(7):2175-80 [1545125.001]
  • [Cites] J Immunol. 1992 Sep 15;149(6):2021-7 [1381393.001]
  • [Cites] Anal Biochem. 1993 May 1;210(2):425-8 [8512082.001]
  • [Cites] J Biol Chem. 1993 Oct 15;268(29):22084-91 [8408066.001]
  • [Cites] Anal Biochem. 1993 Aug 1;212(2):457-68 [8214588.001]
  • (PMID = 16912301.001).
  • [ISSN] 0022-538X
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Viral; 0 / Immunoglobulin Variable Region; 0 / Interleukin-6; 0 / Peptide Library; 0 / Recombinant Proteins; 0 / Viral Proteins
  • [Other-IDs] NLM/ PMC1563863
  •  go-up   go-down


28. Bruce AG, Bakke AM, Gravett CA, DeMaster LK, Bielefeldt-Ohmann H, Burnside KL, Rose TM: The ORF59 DNA polymerase processivity factor homologs of Old World primate RV2 rhadinoviruses are highly conserved nuclear antigens expressed in differentiated epithelium in infected macaques. Virol J; 2009 Nov 18;6:205
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: ORF59 DNA polymerase processivity factor of the human rhadinovirus, Kaposi's sarcoma-associated herpesvirus (KSHV), is required for efficient copying of the genome during virus replication.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virology. 1998 Mar 30;243(1):208-17 [9527930.001]
  • [Cites] Nucleic Acids Res. 1998 Apr 1;26(7):1628-35 [9512532.001]
  • [Cites] J Virol. 1998 Oct;72(10):8458-9 [9766973.001]
  • [Cites] J Virol. 1999 Apr;73(4):3040-53 [10074154.001]
  • [Cites] J Med Virol. 1999 Nov;59(3):346-55 [10502268.001]
  • [Cites] J Virol. 2005 Mar;79(6):3409-18 [15731235.001]
  • [Cites] J Virol. 2005 Jul;79(13):8637-50 [15956606.001]
  • [Cites] Virology. 2005 Sep 30;340(2):183-91 [16043206.001]
  • [Cites] J Virol. 2005 Nov;79(21):13769-77 [16227296.001]
  • [Cites] Virol J. 2005;2:2 [15634356.001]
  • [Cites] Traffic. 2006 Oct;7(10):1322-32 [16911590.001]
  • [Cites] Annu Rev Cell Dev Biol. 2007;23:93-113 [17489688.001]
  • [Cites] Curr Top Microbiol Immunol. 2008;325:153-66 [18637505.001]
  • [Cites] Nucleic Acids Res. 2009 Jul;37(Web Server issue):W222-8 [19443442.001]
  • [Cites] Emerg Infect Dis. 2004 May;10(5):899-902 [15200826.001]
  • [Cites] J Biol Chem. 2004 Jul 2;279(27):28375-86 [15075322.001]
  • [Cites] J Virol. 2004 Sep;78(17):9084-92 [15308704.001]
  • [Cites] Virology. 1991 Sep;184(1):330-40 [1651595.001]
  • [Cites] J Virol. 1992 Aug;66(8):5047-58 [1321287.001]
  • [Cites] Anal Biochem. 1994 Aug 1;220(2):360-6 [7978279.001]
  • [Cites] Genes Dev. 1995 Oct 1;9(19):2335-49 [7557386.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14862-7 [8962146.001]
  • [Cites] J Infect Dis. 1997 Jul;176(1):94-102 [9207354.001]
  • [Cites] J Virol. 1997 Sep;71(9):7083-7 [9261440.001]
  • [Cites] J Virol. 1997 Dec;71(12):9764-9 [9371642.001]
  • [Cites] Virology. 1998 Jan 5;240(1):118-26 [9448696.001]
  • [Cites] J Virol. 1999 Dec;73(12):10320-8 [10559350.001]
  • [Cites] J Virol. 2000 Feb;74(3):1572-7 [10627572.001]
  • [Cites] J Virol. 2000 Apr;74(7):3388-98 [10708456.001]
  • [Cites] N Engl J Med. 2000 Apr 6;342(14):1027-38 [10749966.001]
  • [Cites] Virology. 2000 Apr 10;269(2):335-44 [10753712.001]
  • [Cites] J Virol. 2000 May;74(10):4919-28 [10775636.001]
  • [Cites] J Virol Methods. 2000 Aug;88(2):219-25 [10960709.001]
  • [Cites] Nature. 2000 Sep 14;407(6801):151-2 [11001045.001]
  • [Cites] J Virol. 2000 Dec;74(23):10920-9 [11069986.001]
  • [Cites] J Virol. 2000 Dec;74(24):11993-9 [11090203.001]
  • [Cites] J Virol. 2001 Jan;75(2):891-902 [11134302.001]
  • [Cites] J Virol. 2001 Feb;75(3):1487-506 [11152521.001]
  • [Cites] AIDS. 2000 Dec 1;14(17):F129-35 [11125908.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 2001 Apr 29;356(1408):517-34 [11313009.001]
  • [Cites] Genome Res. 2001 Sep;11(9):1511-9 [11544194.001]
  • [Cites] J Virol. 2002 Oct;76(19):9819-31 [12208960.001]
  • [Cites] Virology. 2003 Jun 20;311(1):60-71 [12832203.001]
  • [Cites] Virology. 2003 Jul 20;312(1):122-34 [12890626.001]
  • [Cites] Virology. 2004 Jan 20;318(2):542-55 [14972523.001]
  • [Cites] J Hum Evol. 1998 Jan;34(1):1-23 [9467779.001]
  • [Cites] J Virol. 1998 Jul;72(7):6228-32 [9621095.001]
  • (PMID = 19922662.001).
  • [ISSN] 1743-422X
  • [Journal-full-title] Virology journal
  • [ISO-abbreviation] Virol. J.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / RR13154; United States / NCRR NIH HHS / RR / R24 RR023343; United States / NCRR NIH HHS / RR / RR023343; United States / NCRR NIH HHS / RR / RR15090; United States / NCRR NIH HHS / RR / R01 RR013154
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Viral; 0 / Antigens, Nuclear; 0 / DNA, Viral; 0 / Viral Proteins; EC 2.7.7.7 / DNA-Directed DNA Polymerase
  • [Other-IDs] NLM/ PMC2785786
  •  go-up   go-down


29. Busnach G, Piselli P, Arbustini E, Baccarani U, Burra P, Carrieri MP, Citterio F, De Juli E, Bellelli S, Pradier C, Rezza G, Serraino D, Immunosuppression and Cancer Study Group: Immunosuppression and cancer: A comparison of risks in recipients of organ transplants and in HIV-positive individuals. Transplant Proc; 2006 Dec;38(10):3533-5
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In both groups, most of the excess risk was attributable to virus-related cancers, such as Kaposi's sarcoma (KS; SIR = 451 in HIV-positive individuals, 125 in transplant recipients), non-Hodgkin's lymphoma (NHL; SIR = 62.1 and 11.1, respectively), and liver cancer (SIR = 9.4 and 4.1, respectively).
  • Significantly increased SIRs for anal cancer and Hodgkin's lymphoma were found only among HIV-positive individuals.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - Organ Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17175324.001).
  • [ISSN] 0041-1345
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


30. Järviluoma A, Child ES, Sarek G, Sirimongkolkasem P, Peters G, Ojala PM, Mann DJ: Phosphorylation of the cyclin-dependent kinase inhibitor p21Cip1 on serine 130 is essential for viral cyclin-mediated bypass of a p21Cip1-imposed G1 arrest. Mol Cell Biol; 2006 Mar;26(6):2430-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • K cyclin encoded by Kaposi's sarcoma-associated herpesvirus confers resistance to the cyclin-dependent kinase (cdk) inhibitors p16Ink4A, p21Cip1, and p27Kip1 on the associated cdk6.

  • PhosphoSitePlus. gene/protein/disease-specific - PhosphoSitePlus® - comprehensive post-translational modification resource .
  • Hazardous Substances Data Bank. L-SERINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 1999 Nov 12;274(46):33161-5 [10551888.001]
  • [Cites] J Natl Cancer Inst. 2005 May 4;97(9):656-66 [15870436.001]
  • [Cites] Curr Opin Genet Dev. 2000 Feb;10(1):70-4 [10679390.001]
  • [Cites] Virology. 2000 Jul 5;272(2):257-66 [10873769.001]
  • [Cites] J Biol Chem. 2000 Oct 6;275(40):31145-54 [10878006.001]
  • [Cites] Biochim Biophys Acta. 2001 Mar 21;1471(3):M123-33 [11250068.001]
  • [Cites] Nat Cell Biol. 2001 Mar;3(3):245-52 [11231573.001]
  • [Cites] J Pathol. 2001 May;194(1):35-42 [11329139.001]
  • [Cites] Oncogene. 2001 Jun 7;20(26):3311-22 [11423981.001]
  • [Cites] Mol Cell Biol. 2001 Aug;21(16):5644-57 [11463845.001]
  • [Cites] J Biol Chem. 2002 Apr 19;277(16):13761-70 [11827966.001]
  • [Cites] J Biol Chem. 2002 Aug 16;277(33):29792-802 [12058028.001]
  • [Cites] Cancer Res. 2003 Jul 1;63(13):3840-4 [12839982.001]
  • [Cites] J Biol Chem. 2003 Jul 11;278(28):25752-7 [12730199.001]
  • [Cites] Cell Cycle. 2004 Feb;3(2):138-40 [14712075.001]
  • [Cites] AIDS Rev. 2003 Oct-Dec;5(4):222-9 [15012001.001]
  • [Cites] J Biol Chem. 2004 Apr 2;279(14):13496-505 [14726525.001]
  • [Cites] Anal Biochem. 1989 Feb 15;177(1):138-43 [2472754.001]
  • [Cites] Anal Biochem. 1991 Feb 1;192(2):262-7 [1852137.001]
  • [Cites] Cell. 1993 Nov 19;75(4):805-16 [8242751.001]
  • [Cites] Mol Cell Biol. 1994 Apr;14(4):2713-21 [8139570.001]
  • [Cites] Cell. 1994 Jul 15;78(1):59-66 [8033212.001]
  • [Cites] EMBO J. 1995 Feb 1;14(3):503-11 [7859739.001]
  • [Cites] J Biol Chem. 1995 Aug 4;270(31):18195-7 [7629134.001]
  • [Cites] Curr Biol. 1996 Apr 1;6(4):474-83 [8723352.001]
  • [Cites] Nature. 1996 Jul 25;382(6589):325-31 [8684460.001]
  • [Cites] Nature. 1996 Aug 1;382(6590):410 [8684480.001]
  • [Cites] Cell Growth Differ. 1996 Feb;7(2):135-46 [8822197.001]
  • [Cites] Blood. 1996 Oct 1;88(7):2648-54 [8839859.001]
  • [Cites] Genes Dev. 1997 Apr 1;11(7):847-62 [9106657.001]
  • [Cites] J Virol. 1997 Jun;71(6):4193-8 [9151805.001]
  • [Cites] Nature. 1997 Nov 13;390(6656):184-7 [9367157.001]
  • [Cites] EMBO J. 1999 Feb 1;18(3):644-53 [9927424.001]
  • [Cites] EMBO J. 1999 Feb 1;18(3):654-63 [9927425.001]
  • [Cites] Gynecol Oncol. 1999 May;73(2):223-8 [10329038.001]
  • [Cites] Genes Dev. 1999 Jun 15;13(12):1501-12 [10385618.001]
  • [Cites] EMBO J. 1999 Oct 1;18(19):5310-20 [10508164.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3349-54 [15271792.001]
  • [Cites] Cell. 1993 Nov 19;75(4):817-25 [8242752.001]
  • [Cites] Science. 1993 Dec 24;262(5142):2050-4 [8266103.001]
  • [Cites] Blood. 2006 Jan 15;107(2):725-32 [16160006.001]
  • [Cites] Mol Carcinog. 2000 Feb;27(2):141-8 [10657906.001]
  • (PMID = 16508017.001).
  • [ISSN] 0270-7306
  • [Journal-full-title] Molecular and cellular biology
  • [ISO-abbreviation] Mol. Cell. Biol.
  • [Language] eng
  • [Grant] United Kingdom / Biotechnology and Biological Sciences Research Council / / BB/C508134/1
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cdkn1a protein, mouse; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Cyclins; 0 / K cyclin protein, Herpesvirus 8, Human; 0 / Recombinant Proteins; 0 / Viral Proteins; 452VLY9402 / Serine; EC 2.7.11.22 / Cdk2 protein, mouse; EC 2.7.11.22 / Cdk6 protein, mouse; EC 2.7.11.22 / Cyclin-Dependent Kinase 2; EC 2.7.11.22 / Cyclin-Dependent Kinase 6
  • [Other-IDs] NLM/ PMC1430279
  •  go-up   go-down


31. Dyson OF, Ford PW, Chen D, Li YQ, Akula SM: Raman tweezers provide the fingerprint of cells supporting the late stages of KSHV reactivation. J Cell Mol Med; 2009 Aug;13(8B):1920-32
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Kaposi's sarcoma-associated herpesvirus (KSHV) has both latent and lytic phases of replication.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virology. 2000 Mar 1;268(1):159-66 [10683338.001]
  • [Cites] Blood. 2005 Jun 1;105(11):4516-22 [15705790.001]
  • [Cites] J Virol. 2001 Jan;75(2):891-902 [11134302.001]
  • [Cites] J Mol Biol. 2001 Mar 30;307(3):899-911 [11273709.001]
  • [Cites] Virology. 2001 Jun 5;284(2):235-49 [11384223.001]
  • [Cites] Eur J Cancer. 2001 Jul;37(10):1251-69 [11423257.001]
  • [Cites] Recent Results Cancer Res. 2002;159:27-37 [11785841.001]
  • [Cites] Oncogene. 2002 Mar 14;21(12):1823-31 [11896614.001]
  • [Cites] Blood. 2002 Aug 1;100(3):888-96 [12130499.001]
  • [Cites] Lancet. 1995 Sep 23;346(8978):799-802 [7674745.001]
  • [Cites] Cancer Res. 1995 Nov 1;55(21):4818-23 [7585513.001]
  • [Cites] Anal Chem. 2005 Jul 15;77(14):4390-7 [16013851.001]
  • [Cites] J Virol Methods. 2005 Nov;129(2):145-51 [15992938.001]
  • [Cites] Biophys J. 2006 Jan 15;90(2):648-56 [16239327.001]
  • [Cites] J Gen Virol. 2006 Mar;87(Pt 3):519-29 [16476973.001]
  • [Cites] J Gen Virol. 2006 May;87(Pt 5):1139-44 [16603514.001]
  • [Cites] Virol J. 2006;3:51 [16805914.001]
  • [Cites] J Electron Microsc (Tokyo). 2007 Jan;56(1):27-36 [17392397.001]
  • [Cites] Intervirology. 2007;50(4):245-53 [17460413.001]
  • [Cites] Virology. 2007 Sep 1;365(2):336-45 [17490703.001]
  • [Cites] PLoS One. 2007;2(8):e811 [17726541.001]
  • [Cites] PLoS Pathog. 2007 Oct 19;3(10):1388-400 [17953479.001]
  • [Cites] Int J Cancer. 2007 Dec 15;121(12):2723-8 [17724716.001]
  • [Cites] J Clin Invest. 2004 Jan;113(1):124-36 [14702116.001]
  • [Cites] J Biomed Opt. 2003 Apr;8(2):173-8 [12683842.001]
  • [Cites] Biophys J. 2003 Jun;84(6):3968-81 [12770902.001]
  • [Cites] Biopolymers. 2003;72(4):230-40 [12833477.001]
  • [Cites] J Clin Invest. 2004 Jan;113(1):21-3 [14702103.001]
  • [Cites] Mol Cell. 2004 Mar 12;13(5):713-23 [15023341.001]
  • [Cites] Oncogene. 2004 Jul 1;23(30):5227-41 [15122343.001]
  • [Cites] Clin Chem. 2004 Sep;50(9):1597-606 [15247154.001]
  • [Cites] Ann Intern Med. 1984 Jun;100(6):866-80 [6326635.001]
  • [Cites] J Behav Med. 1985 Sep;8(3):249-60 [3003360.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Jul;86(13):4987-91 [2740335.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1991 Apr;32(5):1558-61 [1849874.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jul 3;92(14):6289-93 [7603984.001]
  • [Cites] Methods Enzymol. 1995;254:114-24 [8531680.001]
  • [Cites] Nat Med. 1996 Mar;2(3):342-6 [8612236.001]
  • [Cites] J Virol. 1997 Jan;71(1):715-9 [8985403.001]
  • [Cites] AIDS. 1997 Sep;11(11):1327-32 [9302441.001]
  • [Cites] J Virol. 1997 Oct;71(10):7963-8 [9311888.001]
  • [Cites] J Virol. 1998 Jul;72(7):6223-7 [9621094.001]
  • [Cites] Biophys J. 1998 Jul;75(1):70-91 [9649369.001]
  • [Cites] Curr Clin Top Infect Dis. 1998;18:237-51 [9779358.001]
  • [Cites] Mol Cell Biol. 1999 Apr;19(4):2690-8 [10082535.001]
  • [Cites] Biospectroscopy. 1999;5(3):151-67 [10380082.001]
  • [Cites] Leukemia. 2005 Jan;19(1):18-26 [15470486.001]
  • [Cites] J Virol. 2005 Feb;79(4):2626-30 [15681463.001]
  • [Cites] J Agric Food Chem. 2005 Feb 23;53(4):845-52 [15712988.001]
  • [Cites] Oncol Rep. 2005 May;13(5):837-46 [15809747.001]
  • [Cites] J Virol. 2000 Jul;74(13):5896-901 [10846070.001]
  • (PMID = 18752634.001).
  • [ISSN] 1582-4934
  • [Journal-full-title] Journal of cellular and molecular medicine
  • [ISO-abbreviation] J. Cell. Mol. Med.
  • [Language] ENG
  • [Grant] United States / NIBIB NIH HHS / EB / EB006483-02; United States / NIBIB NIH HHS / EB / R21 EB006483-02; United States / NIBIB NIH HHS / EB / R21 EB006483; United States / NIBIB NIH HHS / EB / R21 EB006483-01A1; United States / NIBIB NIH HHS / EB / R21EB006483; United States / NIBIB NIH HHS / EB / EB006483-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS90700; NLM/ PMC2819606
  •  go-up   go-down






Advertisement